2013

Mechanistic Basis for Atrial and Ventricular Arrhythmias Caused by KCNQ1 Mutations

Daniel C. Bartos

University of Kentucky, danielcbartos@gmail.com

Click here to let us know how access to this document benefits you.

Recommended Citation

Bartos, Daniel C., "Mechanistic Basis for Atrial and Ventricular Arrhythmias Caused by KCNQ1 Mutations" (2013). Theses and Dissertations--Physiology. 8.
https://uknowledge.uky.edu/physiology_etds/8

This Doctoral Dissertation is brought to you for free and open access by the Physiology at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Physiology by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
STUDENT AGREEMENT:

I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained and attached hereto needed written permission statements(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine).

I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. I agree that the document mentioned above may be made available immediately for worldwide access unless a preapproved embargo applies.

I retain all other ownership rights to the copyright of my work. I also retain the right to use in future works (such as articles or books) all or part of my work. I understand that I am free to register the copyright to my work.

REVIEW, APPROVAL AND ACCEPTANCE

The document mentioned above has been reviewed and accepted by the student’s advisor, on behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of the program; we verify that this is the final, approved version of the student’s dissertation including all changes required by the advisory committee. The undersigned agree to abide by the statements above.

Daniel C. Bartos, Student
Dr. Brian P. Delisle, Major Professor
Dr. Bret N. Smith, Director of Graduate Studies
ABSTRACT OF DISSERTATION

MECHANISTIC BASIS FOR ATRIAL AND VENTRICULAR ARRHYTHMIAS CAUSED BY KCNQ1 MUTATIONS

Cardiac arrhythmias are caused by a disruption of the normal initiation or propagation of electrical impulses in the heart. Hundreds of mutations in genes encoding ion channels or ion channel regulatory proteins are linked to congenital arrhythmia syndromes that increase the risk for sudden cardiac death. This dissertation focuses on how mutations in a gene (KCNQ1) that encodes a voltage-gated K⁺ ion channel (Kv7.1) can disrupt proper channel function and lead to abnormal repolarization of atrial and ventricular cardiomyocytes.

In the heart, Kv7.1 coassembles with a regulatory protein to conduct the slowly activating delayed rectifier K⁺ current (I_{Ks}). Loss-of-function KCNQ1 mutations are linked to type 1 long QT syndrome (LQT1), and typically decrease I_{Ks}, which can lead to ventricular action potential (AP) prolongation. In patients, LQT1 is often characterized by an abnormally long corrected QT (QTc) interval on an electrocardiogram (ECG), and increases the risk for polymorphic ventricular tachycardias.

KCNQ1 mutations are also linked to atrial fibrillation (AF), but cause a gain-of-function phenotype that increases I_{Ks}. Surprisingly, patients diagnosed with both LQT1 and AF are increasingly identified as genotype positive for a KCNQ1 mutation. The first aim of this dissertation was to determine a unique functional phenotype of KCNQ1 mutations linked to both arrhythmia syndromes by functional analysis via the whole-cell patch clamp technique in HEK293 cells.

A proportion of patients with LQT1-linked KCNQ1 mutations do not have abnormal QTc prolongation known as latent LQT1. Interestingly, exercise can reveal abnormal QTc prolongation in these patients. During exercise, β-adrenergic activation stimulates PKA to phosphorylate Kv7.1, causing an increase in I_{Ks} to prevent ventricular AP prolongation. Therefore, the second aim of this dissertation was to determine a molecular mechanism of latent LQT1 through functional analyses in HEK293 cells while incorporating pharmacological
and phosphomimetic approaches to study PKA regulation of mutant Kv7.1 channels.

The findings in this dissertation provide new insight into how $KCNQ1$ mutations disrupt the function of Kv7.1 in a basal condition or during β-adrenergic activation. Also, this dissertation suggests these approaches will improve patient management by identifying mutation specific risk factors for patients with $KCNQ1$ mutations.

KEYWORDS: congenital arrhythmia syndromes, voltage-gated potassium ion channels, cardiac action potential, long QT syndrome, atrial fibrillation

Daniel C. Bartos
Student’s Signature

June 5, 2013
Date
MECHANISTIC BASIS FOR ATRIAL AND VENTRICULAR ARRHYTHMIAS
CAUSED BY KCNQ1 MUTATIONS

By

Daniel C. Bartos

Brian P. Delisle, Ph.D.
Director of Dissertation

Bret N. Smith, Ph.D.
Director of Graduate Studies

June 5, 2013
Date
# TABLE OF CONTENTS

List of Tables ........................................................................................................................................ vi

List of Figures ......................................................................................................................................... vii

Chapter 1: Introduction

1.1 Congenital arrhythmia syndromes ................................................................................................. 1
1.2 Electrical properties of the heart and the cardiac AP ................................................................. 2
  1.2.1 Electrical properties of the heart ............................................................................................ 2
  1.2.2 Cardiac ion channels and the cardiac AP .............................................................................. 3
1.3 KCNQ1 cloning, protein expression, & Kv7.1’s role in the human heart .................................. 5
1.4 Congenital long QT syndrome and KCNQ1 .................................................................................. 7
  1.4.1 Congenital long QT syndrome .............................................................................................. 7
  1.4.2 Diagnosis of long QT syndrome ............................................................................................ 8
  1.4.3 KCNQ1 and type 1 long QT syndrome .................................................................................. 9
1.5 Atrial fibrillation and KCNQ1 ......................................................................................................... 10
  1.5.1 Familial atrial fibrillation ....................................................................................................... 10
  1.5.2 LQT1, atrial fibrillation, and KCNQ1 .................................................................................... 11
1.6 Regulation of I_{Ks} by PKA phosphorylation and β-adrenergic receptor stimulation ................. 13
  1.6.1 Adrenergic stimulation in the heart and regulation of the funny current and intracellular calcium ........................................................................................................ 13
  1.6.2 PKA phosphorylates the N-terminus of Kv7.1 to increase I_{Ks} and prevent ventricular AP prolongation during sympathetic stimulation ...................................................... 15
  1.6.3 PKA regulation of Kv7.1 and LQT1 ....................................................................................... 16
1.7 Purpose of dissertation .................................................................................................................... 17
  1.7.1 Overview of dissertation project ........................................................................................... 17
  1.7.2 Hypothesis and specific aims ............................................................................................... 18
  1.7.3 Significance of findings ......................................................................................................... 18

Chapter 2: Methods

2.1 Site directed mutagenesis ............................................................................................................... 22
2.2 Cell culture and transfection ......................................................................................................... 22
2.3 Electrophysiology ......................................................................................................................... 23
2.4 Cell lysis ........................................................................................................................................... 25
2.5 Protein quantification ..................................................................................................................... 26
2.6 Biotinylation .................................................................................................................................... 26
2.7 Statistical Analysis ......................................................................................................................... 27

Chapter 3: R231C-Kv7.1 is associated with pleiotropic function and expressivity of LQT1 and familial AF

3.1 Introduction ..................................................................................................................................... 30
3.2 Clinical evaluation .......................................................................................................................... 31
  3.2.1 Study population and diagnostic criterion ............................................................................. 31
  3.2.2 Genetic analysis ...................................................................................................................... 31
3.3 Results......................................................................................................................... 32
3.3.1 R231C is linked to LQT1, fetal bradycardia, and early-onset AF ...... 32
3.3.2 R231C-Kv7.1 conducts large $I_{\text{Kv7.1}}$ and causes a gain-of-function ... 34
3.3.3 Coexpression of WT- and R231C-Kv7.1 yields a mixed functional
phenotype............................................................................................................................. 35
3.3.4 Coexpression of WT- and R231C-Kv7.1 reduced $I_{\text{Kv7.1}}$ at diastolic
potentials when recorded using a ventricular AP waveform at 37°C........ 37
3.3.5 Constitutive $I_{\text{Kv7.1}}$ of R231C-Kv7.1 is not dependent of KCNE1
expression............................................................................................................................... 38
3.4 Discussion...................................................................................................................... 38

Chapter 4: R231H-Kv7.1 provides direct evidence of a $\text{KCNQ1}$ mutation causing
early-onset atrial fibrillation
4.1 Introduction .................................................................................................................. 53
4.2 Results ......................................................................................................................... 54
  4.2.1 Genetic screening........................................................................................................ 54
  4.2.2 R231H-Kv7.1 is prevalent among families with a history of familial
  early-onset atrial fibrillation................................................................................................. 55
  4.2.3 Cells coexpressing WT- and R231H-Kv7.1 increase $I_{\text{Kv7.1}}$ at negative
  potentials, but do not decrease maximally activated $I_{\text{Kv7.1}}$............................... 57
  4.2.4 Cells coexpressing WT- and R231H-Kv7.1 increase $I_{\text{Kv7.1}}$ when
  recorded using an atrial AP waveform............................................................................. 59
  4.2.5 R231H-Kv7.1 preferentially shortens the atrial AP duration in
  computational simulations................................................................................................. 59
  4.2.6 Cells coexpressing KCNE3 and R231H-Kv7.1 decrease voltage-
dependent gating of activation.......................................................................................... 60
  4.2.7 Parallel functional analysis of AF-linked $\text{KCNQ1}$ mutations that elicit
  constitutive activation of Kv7.1 ....................................................................................... 61
4.3 Discussion....................................................................................................................... 63

Chapter 5 PKA insensitive Kv7.1 mutants identify with latent type 1 long QT
syndrome
5.1 Introduction .................................................................................................................. 79
5.2 Results ......................................................................................................................... 80
  5.2.1 Patients genotype positive for I235N-Kv7.1 have latent LQT1....... 80
  5.2.2 Cells expressing I235N-Kv7.1 largely reduce $I_{\text{Kv7.1}}$, but coexpression of
  WT- and I235N-Kv7.1 alleviates the reduction in $I_{\text{MAX}}$......................................... 81
  5.2.3 Cells coexpressing WT- and I235N-Kv7.1 prevent PKA stimulation of
  $I_{\text{Kv7.1}}$ and phosphomimetic substitution at S27 does not increase $I_{\text{Kv7.1}}$..... 82
  5.2.4 Computational simulations suggest $I_{\text{KS}}$ insensitivity to PKA likely
  contributes to ventricular AP prolongation with β-adrenergic stimulation.. 83
5.3 Discussion....................................................................................................................... 84

Chapter 6 General Discussion .......................................................................................... 97
  6.1 Overall significance..................................................................................................... 97
6.2 *KCNQ1* mutations associated with a mixed clinical phenotype of long QT syndrome and atrial fibrillation .................................................................................................................. 98
6.3 Recent discoveries of patients genotype positive for R231C-Kv7.1 and importance for understanding pleiotropic mutations .......................................................................................... 100
6.4 Exercise treadmill stress testing correlates clinical observations with a molecular mechanism ......................................................................................................................... 102
6.5 Kv7.1 voltage sensor mutations .................................................................................................................. 107
6.6 Concluding Statement ............................................................................................................................ 109
6.7 Future studies ...................................................................................................................................... 110

Appendix A. Limitations ............................................................................................................................ 118

References .................................................................................................................................................. 120

Vita ......................................................................................................................................................... 134
LIST OF TABLES

Chapter 1
  1.1 Genes associated with specific subtypes of congenital LQTS ............ 20
  1.2 The Schwartz score criteria for diagnosing LQTS patients ............... 21

Chapter 2
  2.1 Mutagenesis primer sequences for Kv7.1 plasmid DNA ................... 29

Chapter 3
  3.1 QTc values for patients genotype positive for R231C-Kv7.1 ............. 52

Chapter 5
  5.1 Clinical characteristics of patients genotype positive for I235N-Kv7.1 ... 96

Chapter 6
  6.1 Clinical characteristics of families genotype positive for KCNQ1 mutations linked to early-onset AF ................................................................. 115
FIGURES

Chapter 1
1.1 A cartoon of one Kv7.1 α-subunit and KCNE1 β-subunit.......................... 19

Chapter 3
3.1 R231C-Kv7.1 genotype positive families ............................................. 42
3.2 Cells expressing R231C-Kv7.1 conduct large, constitutive \( I_{\text{Kv7.1}} \) ........ 43
3.3 Cells coexpressing WT- and R231C-Kv7.1 yield a bipartite functional phenotype ................................................................. 44
3.4 Cell surface expression of R231C-Kv7.1 .............................................. 46
3.5 Cells coexpressing WT- and R231C-Kv7.1 generate constitutively activated \( I_{\text{Kv7.1}} \) and reduce \( I_{\text{Kv7.1}} \) during ventricular AP repolarization .............. 48
3.6 Cells expressing R231C-Kv7.1 conduct constitutive \( I_{\text{Kv7.1}} \) without expressing KCNE1 ................................................................. 50
3.7 Computational simulations of human atrial and ventricular AP .............. 51

Chapter 4
4.1 R231H-Kv7.1 confers a high risk for early-onset AF .............................. 66
4.2 Cells coexpressing WT- and R231H-Kv7.1 do not reduce \( I_{\text{MAX}} \) .......... 68
4.3 Cells coexpressing WT- and R231H-Kv7.1 generate constitutive \( I_{\text{Kv7.1}} \) similar to R231C-Kv7.1 ................................................................. 70
4.4 R231H-Kv7.1 does not alter cell surface expression ................................. 71
4.5 Coexpressing WT- and R231H-Kv7.1 increases \( I_{\text{Kv7.1}} \) when measured using an atrial AP waveform at physiological temperature .................................. 72
4.6 R231H-Kv7.1 is predicted to shorten the atrial AP duration .................... 73
4.7 Coexpression of R231H-Kv7.1 and KCNE3 decreases \( I_{\text{MAX}} \) .......... 75
4.8 Analysis of AF-linked KCNQ1 mutations ............................................. 77

Chapter 5
5.1 Patients genotype positive for I235N-Kv7.1 demonstrate exaggerated QTc prolongation following exercise treadmill stress testing ....................... 86
5.2 The loss-of-function caused by I235N-Kv7.1 is mostly corrected by coexpression of WT-Kv7.1 ................................................................. 88
5.3 \( I_{\text{Kv7.1}} \) recorded from cells coexpressing WT- and I235N-Kv7.1 is insensitive to PKA stimulation ................................................................. 90
5.4 Phosphomimetic substitution of S27D does not increase \( I_{\text{Kv7.1}} \) for I235N-Kv7.1 ......................................................................................... 92
5.5 Computational simulations of ventricular AP with or without β-adrenergic stimulation .................................................................................... 94

Chapter 6
6.1 Analysis of step pulse for AF-linked mutants at 1, 2, and 5 seconds ...... 113
6.2 R231H-Kv7.1 is insensitive to PKA stimulation ...................................... 115
Chapter 1

Introduction

1.1 Congenital arrhythmia syndromes

Each year, thousands of people die from sudden cardiac death due to cardiac arrhythmias.¹ Most cases are due to underlying conditions such as coronary artery disease or structural remodeling of the heart, but a proportion is caused by defects in cardiac electrophysiology. Some patients with arrhythmias primarily due to electrophysiological issues have a genetic predisposition, and a common cause is an inherited or congenital arrhythmia syndrome. Therefore, identifying genetic mutations in families at risk can provide a link between clinical phenotypes and molecular mechanisms. Mutations associated with congenital arrhythmia syndromes are often identified in ion channel genes, and they typically disrupt ion channel function to disorder the normal electrophysiology of the heart. Understanding the molecular mechanism and functional phenotypes of mutations linked to congenital arrhythmias can provide insight into clinical diagnosis and therapeutic intervention of current and future generations.

In this dissertation, I focus on one cardiac ion channel macromolecular complex, and show how single mutations are capable of altering protein function, the cardiac action potential (AP), and arrhythmia susceptibility to predispose patients to multiple clinical phenotypes. My work demonstrates the importance of proper ion channel function in the heart, and how disrupting the function of one protein can be detrimental to one’s well being.
In this chapter, I briefly introduce the different types of cardiac ion channels and their roles in generating ionic currents that shape the cardiac AP. I then, focus on the voltage-gated K\(^+\) ion channel, Kv7.1, which conducts the slowly activating component of the delayed rectifier K\(^+\) current (I\(_{Ks}\)) important for normal repolarization. Given the focus on Kv7.1, the remainder of this chapter discusses mutations within the Kv7.1 gene (KCNQ1) that associate with different clinical phenotypes and how different mutations in Kv7.1 might lead to an increased risk for atrial and/or ventricular arrhythmias.

1.2 Electrical properties of the heart and the cardiac AP

1.2.1 Electrical properties of the heart

The coordinated contractions of the human heart are controlled by continuous electrical signals that spontaneously originate in the pacemaker cells of the sinoatrial node.\(^2\) The electrical signals generate an AP in individual cells that can propagate to adjacent cells that are electrically coupled by gap junction connexin hemichannels.\(^3\) APs are a direct result from the opening and closing of ion channels. Different regions in the heart express different ion channels, which alters the shape of the AP waveform in specific regions throughout the cardiac tissue and promotes the unidirectional propagation of the electrical waveform electromechanically coupling the heart.\(^4\)\(^-\)\(^6\) From the sinoatrial node, the electrical waveform propagates through the atrial tissue to the atrioventricular node, and it is then conducted through the bundles of His towards the apex of the heart.
Lastly, the electrical waveform propagates throughout the ventricular tissue via the Purkinje fibers coordinating excitation-contraction coupling.

1.2.2 Cardiac ion channels and the cardiac AP

Ion channels play an important role in shaping the AP in cardiomyocytes. Ion channels are transmembrane proteins that allow movement of charged ions (K⁺, Ca²⁺, Na⁺) across the plasma membrane down their electrochemical gradient through a selective pore domain. Many ion channels expressed in cardiomyocytes are voltage-gated; whereas, they have a voltage-sensing domain consisting of conserved positively charged amino acid residues in the fourth transmembrane segment (S4) that moves in response to changes in membrane potential to open and close the pore. The opening and closing of ion channels alter the membrane permeability and membrane potential to generate an AP.

The most common types of voltage-gated ion channels are voltage-gated Na⁺ (Nav), voltage-gated Ca²⁺ (Cav), and voltage-gated K⁺ (Kv) channels. Generally, the rapid upstroke or depolarization of the membrane in atrial and ventricular myocytes (phase 0) is due to the opening or activation of Nav channels. Rapid inactivation of Nav channels and the activation of transient outward Kv channels generate the “notch” phase (phase 1), which is a partial repolarization of the membrane. Cav channels also activate due to depolarization, but the time course of activation is slower than Nav channels. During the plateau phase, L-type Cav channels conduct inward Ca²⁺ current ($I_{Ca,L}$) that is important for calcium-induced-calcium release that controls the
excitation-contraction coupling of cardiomyocytes.\textsuperscript{13} The delayed rectifier Kv channels are the slowest to activate, and activate during the plateau phase to conduct outward $K^+$ currents ($I_{K}$). During the plateau phase, the AP waveforms of cardiomyocytes maintain depolarized for hundreds of milliseconds because of a balance between inward $I_{Ca,L}$ and outward $I_{K}$. As Cav channels inactivate, the outward $I_{K}$ predominate, and repolarization (phase 3) occurs.

The delayed rectifier Kv channels are comprised of two Kv channels (Kv7.1 and Kv11.1) that conduct distinct components: the slowly and rapidly activating delayed rectifier $K^+$ currents ($I_{Ks}$ and $I_{Kr}$, respectively).\textsuperscript{14} These channels differ in their time- and voltage-dependent functions as well as drug sensitivities and regional distribution. In addition to the delayed rectifier Kv channels, a third $K^+$-selective ion channel contributes to the repolarization phase and is the voltage-independent inward-rectifying $K^+$-channel (Kir). It is most permeable at negative membrane potentials and contributes to the resting membrane potential (phase 4) of the AP waveforms.\textsuperscript{15, 16}

The distinct waveforms of the atrial and ventricular AP are crucial for the propagation of electrical signaling and excitation-contraction coupling of the heart. This requires the proper functioning and regional distribution of many different ion channels (Nav, Cav, Kv, Kir, and more). Interestingly, mutations in the ion channels encoding genes are linked to congenital arrhythmia syndromes and disrupt normal ion channel function leading to abnormalities of AP waveforms.

My entire dissertation project focuses on how mutations associated to a delayed rectifier Kv channel (Kv7.1) can disrupt the properties of $I_{Ks}$ and thus,
repolarization of the atrial and ventricular AP waveforms. Mutations within the
gene encoding Kv7.1 (KCNQ1) are linked to the most common congenital
arrhythmia syndrome, type 1 long QT syndrome. In the following sections, I
explain the history of how Kv7.1 was originally linked to arrhythmias, how Kv7.1
contributes to the atrial and ventricular AP, and how Kv7.1 dysfunction
contributes to atrial and ventricular congenital arrhythmia syndromes.

1.3 KCNQ1 cloning, protein expression, and Kv7.1’s role in the human heart

In 1996, positional cloning identified KCNQ1 to chromosome 11p15.5 as the
causative gene responsible for the most common congenital arrhythmia
syndrome, type 1 long QT syndrome (LQT1, which will be discussed in detail in
section 1.4). KCNQ1 encodes the pore forming Kv7.1 α-subunit and is a
member of a family of slow delayed rectifier K⁺ channels that includes Kv7.2-
7.5. Similar to other voltage-gated K⁺ α-subunits, Kv7.1 consists of six α-helical
transmembrane segments (S1-S6), intracellular amino- (N-) and carboxyl- (C-)
termini, and is functional as a tetrameric protein embedded in the plasma
membrane (Figure 1.1). The transmembrane segments S1-S4 comprise the
voltage-sensing domain, and S5-S6 form the K⁺-selective pore. Positively
charged amino acid residues are highly conserved in S4 among voltage-gated K⁺
channels, while negatively charges amino acid residues are conserved within S1-
S3. These charged residues maintain important electrostatic interactions
between each other in order to stabilize Kv7.1 in a state-dependent manner and
enable Kv7.1 to respond to changes in transmembrane potentials.
In humans, Kv7.1 is expressed in a wide range of cell types including cardiomyocytes and a variety of epithelial cells (lung, stomach, pancreas, cochlea, intestine, and kidneys), but Kv7.1 is the only member of the Kv7.x family not identified in neuronal tissue.\textsuperscript{19,20} Kv7.1 has different tissue-specific functions as it may contribute to repolarization of the cardiac AP or transmembrane transport of water and salts in epithelial tissues.\textsuperscript{21-25} Based on location and function, Kv7.1 forms different heteromeric channel complexes with an assortment of KCNE β-subunits (KCNE1-5), and each β-subunit interact with Kv7.1 to generate unique functional phenotypes.\textsuperscript{26-28} For instance, coexpression of wild-type Kv7.1 (WT-Kv7.1) with KCNE1 in a heterologous system results in large increases in macroscopic Kv7.1 current (\(I_{Kv7.1}\)), the time course of activation or deactivation are slowed, and Kv7.1 inactivation is almost completely suppressed (Figure 1.1).\textsuperscript{24,25} Coexpression of WT-Kv7.1 with either KCNE2 or KCNE3 generates constitutive (increases the open probability at resting or negative membrane potentials) \(I_{Kv7.1}\); whereas, \(I_{Kv7.1}\) amplitude is much larger when expressed with KCNE3 than cells expressing KCNE2.\textsuperscript{29,30} When expressed with KCNE4, \(I_{Kv7.1}\) is largely reduced, and KCNE5 shifts voltage dependence of activation positively while slowing the time course of activation of Kv7.1 similar to KCNE1.\textsuperscript{31}

In the heart, Kv7.1 most commonly coassembles with KCNE1 to conduct \(I_{Ks}\), which is critical for the repolarization phase of the atrial and ventricular AP (heterologous expression of Kv7.1 and KCNE1 yields \(I_{Kv7.1}\) that resembles native \(I_{Ks}\)).\textsuperscript{24,25} The cardiac AP duration is characterized by a long depolarized plateau
phase (100s of ms), and the duration of the plateau is influenced by the balance of inward depolarizing or outward repolarizing ionic currents.\textsuperscript{32} I\textsubscript{Ks}, along with two other K\textsuperscript{+}-selective currents (I\textsubscript{Kr} and I\textsubscript{K1}) constitutes the “repolarization reserve” of the cardiac AP.\textsuperscript{33,34} All three currents are important for controlling the cardiac AP duration and the resting membrane potential. Mutations within the three genes encoding the pore-forming α-subunits of these K\textsuperscript{+}-selective currents, KCNQ1, KCNH2, and KCNJ2, can disrupt I\textsubscript{Ks}, I\textsubscript{Kr}, or I\textsubscript{K1} and are all linked to subtypes of congenital long QT syndrome, LQTS (LQT1, LQT2, and LQT7, respectively).\textsuperscript{33-37}

1.4 Congenital long QT syndrome and KCNQ1

1.4.1 Congenital long QT syndrome

Congenital LQTS is a disease affecting cardiomyocyte repolarization with a prevalence of ~1 in 2500 patients and is linked to thirteen genes encoding ion channels or regulatory counterparts (LQT1-LQT13, see Table 1.1 for overview of genes linked to LQTS).\textsuperscript{38,39} LQTS patients are typically characterized by borderline to prolonged resting corrected QT intervals (QTc intervals) on an electrocardiogram (ECG), and have an increased risk for life-threatening events such as syncope, polymorphic ventricular tachycardias, and sudden cardiac death.\textsuperscript{40-42} Increased risk of sudden cardiac death correlates with a patient’s family history, gender, QTc interval, and incidents of syncope or tachycardia.\textsuperscript{43} LQTS was originally known as the autosomal dominant Romano-Ward syndrome or the more severe form of autosomal recessive Jervell-Lange-Nielsen syndrome.
that is associated with deafness and compound mutations in \textit{KCNQ1} and/or \textit{KCNE1}.\textsuperscript{44, 45}

1.4.2 Diagnosis of long QT syndrome

On a surface ECG, the QRS complex corresponds to the upstroke (phase 0) of the AP of ventricular tissue and the T wave corresponds to ventricular AP repolarization (phase 3). Therefore, the QT interval reflects the duration of the ventricular AP. Typically in the clinic, a QT interval is adjusted for an individual's heart rate by various formulas and is reported as the QTc interval.\textsuperscript{46-48} The most commonly used formula to calculate QTc intervals is the Bazett formula:

\[
\text{QTc} = \frac{\text{QT}}{\sqrt{\text{RR}}}
\]

Based on this formula, a QTc interval is considered prolonged when it is $\geq 450$ ms for males or $\geq 460$ ms for females.\textsuperscript{49} The diagnosis of LQTS is not as straightforward as it would seem because the observation of a patient with a prolonged QTc interval does not necessitate an LQTS diagnosis. In order for an individual to be diagnosed with LQTS, several criteria must be met using a scoring system that ranks a combination of symptoms, family history, and ECG observations, called the Schwartz score (see Table 1.2).\textsuperscript{50} Complicating this issue is that there is a high amount of variability in ECG characteristics within families and nearly 50% of genotype positive LQTS patients do not have obvious ECG abnormalities. Specifically, nearly 40% of LQT1, 20% of LQT2, and 10% of LQT3 patients have normal QTc intervals at rest (concealed or latent LQTS).\textsuperscript{51} Recent studies show that incorporating exercise treadmill or epinephrine stress
testing can expose QTc interval prolongation in patients with latent LQTS, and these advanced tools can predict specific subtypes of LQTS such as latent LQT1 or LQT2.\textsuperscript{52, 53} The Schwartz score was set up as a system to address the probability of having LQTS when genetic testing was not readily available and studies suggest that the Schwartz score under predicts the actual number of affected patients.\textsuperscript{54} Therefore, a combination of genetic testing with more advanced clinical tools may help increase the accuracy and diagnosis of LQTS.

\textit{1.4.3 \textit{KCNQ1} and type 1 long QT syndrome}

One of the most challenging types of LQTS to diagnose is LQT1 because a high percentage of patients have a normal resting QTc interval. LQT1 is one of the most common types of LQTS that represents > 40\% of LQTS cases.\textsuperscript{38} LQT1 is linked to hundreds of “loss-of-function” missense \textit{KCNQ1} mutations that cause LQT1 by decreasing $I_{\text{KS}}$ by disrupting Kv7.1 vesicular transport (trafficking), protein folding, and/or gating permeation.\textsuperscript{17} A reduction in $I_{\text{KS}}$ reduces the repolarization reserve in a ventricular myocyte, which can lead to ventricular AP prolongation. A prolonged ventricular AP duration predisposes ventricular myocytes to early afterdepolarizations (EAD) or it can cause a dispersion of ventricular repolarization in certain regions of the ventricular wall.\textsuperscript{32, 55} Spatial differences in AP duration or repolarization can create ‘pockets’ of inexcitable myocardial tissue leading to regions of conduction block that increase the risk for electrical impulse reentry.\textsuperscript{55-57} The resulting EADs or functional reentry can culminate into the phenotypic polymorphic ventricular tachycardia (torsades de
pointes), and if no intervention follows, these arrhythmias can transform into ventricular fibrillation or sudden cardiac death.

1.5 Atrial fibrillation and KCNQ1

1.5.1 Familial atrial fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia syndrome, and is characterized by rapid and irregular contractions of the atrial tissue.\textsuperscript{58} AF increases the risk for palpitations, syncope, congestive heart failure, thrombus, and stroke, and it is estimated that the lifetime risk for development of AF at age > 40 years is one in four people.\textsuperscript{59,60} AF usually is secondary to underlying heart disease, hypertension, structural or electrical remodeling, or hyperthyroidism. However, the disease can present without such symptoms and is known as lone AF. Interestingly, \textasciitilde30\% of AF patients have a family history of AF, suggesting a genetic predisposition.\textsuperscript{61}

Familial AF with autosomal dominant transmission of lone AF was originally reported in 1943, but it was not until 2003 that a causative gene was identified.\textsuperscript{62,63} A KCNQ1 mutation was identified through linkage analysis with the autosomal dominant form of familial AF in a multigenerational family, and the mutation (S140G-Kv7.1) generates a unique functional phenotype. Voltage-clamp analysis revealed that cells expressing S140G-Kv7.1 increase the open probability of Kv7.1 at negative potentials generating constitutive $I_{Kv7.1}$ at resting membrane potentials, and the mutation was defined as a “gain-of-function”.\textsuperscript{63} Since this initial discovery, several other KCNQ1 mutations are suspected to cause familial
or sporadic cases of AF. All are considered gain-of-function mutations because they generate constitutive $I_{Kv7.1}$ or slow the time course of deactivation.$^{64-66}$ Interestingly, mutations in several other genes ($KCNE2$, $KCNE5$, and $NPPA$) that regulate the $I_{Ks}$ channel complex also associate with AF and studies suggest they cause an increase in $I_{Kv7.1}$. $^{66-68}$ Together, these findings validate the critical roles $Kv7.1$ and $I_{Ks}$ have in atrial repolarization.

An increase in $I_{Ks}$ is expected to shorten the atrial AP duration and reduce the effective refractory period.$^{11}$ Shorter atrial AP durations or reduced effective refractory periods increase the excitability of the myocyte. If the effective refractory period is shorter than the time it takes a premature electrical stimulus to reach this origin, then a subsequent AP can fire and multiple reentry circuits can develop if the propagating impulse does not stop.$^{55, 58, 69}$ Multiple reentry circuits increase rapid conduction, disorganize the homogeneity of atrial contraction, and serve as the primary drive for AF.$^{69}$

### 1.5.2 LQT1, atrial fibrillation, and KCNQ1

Recent findings indicate that 2% of LQTS patients have early-onset AF (age < 50 years) compared to the 0.1% prevalence of AF in the background population.$^{70}$ The majority of patients in this LQTS cohort who had early-onset AF have an LQT1 mutation. The observation of one patient with a single mutation having LQT1 and AF is perplexing because of the loss- or gain-of-function $Kv7.1$ phenotype associated with LQT1- or AF-linked $KCNQ1$ mutations, respectively. Interestingly, nine out of sixteen patients in the family genotype positive for
S140G-Kv7.1 have prolonged QTc intervals. This is counterintuitive because S140G-Kv7.1 is defined as a gain-of-function mutation and is predicted to shorten the atrial AP duration.

Thus far three other KCNQ1 variants linked to early-onset AF have been studied, insIAP54-56-Kv7.1, V141M-Kv7.1, and S209P-Kv7.1. The insIAP54-56-Kv7.1 variant is a polymorphism that has been identified in several control patients, which suggests it is not a primary cause of AF. Similar to S140G-Kv7.1, both V141M-Kv7.1 and S209P-Kv7.1 are only identified in a single family each. The lone V141M-Kv7.1 patient was an infant with a short QT interval, and the S209P-Kv7.1 family members have normal QTc intervals. Voltage-clamp studies with coexpression of WT-Kv7.1 and KCNE1 show that V141M-Kv7.1 and S209P-Kv7.1 increase $I_{Kv7.1}$ activation at negative membrane potentials, but their effects on amplitude of maximally activated $I_{Kv7.1}$ ($I_{\text{MAX}}$) at positive potentials were not directly studied.

One additional mutation to consider is Q147R-Kv7.1, which was identified in a female patient with borderline QTc interval prolongation and persistent AF at the age of 83 years. The fact that the patient was diagnosed with AF at such a late stage in life and no other relatives were genotype positive or had AF warrants whether or not this mutation is actually AF-causing. Nonetheless, voltage-clamp studies show Q147R-Kv7.1 causes a unique functional phenotype that is dependent on coexpression of KCNE β-subunits. Compared to WT-Kv7.1 expressing cells, cells coexpressing Q147R-Kv7.1 with KCNE1 yield smaller
$I_{Kv7.1}$; whereas, larger $I_{Kv7.1}$ was measured from cells coexpressing Q147R-Kv7.1 and KCNE2.

Whether or not there is a unique functional phenotype of Kv7.1 mutant channels associated with LQT1 and AF has yet to be determined. Identifying a mechanism of how a single mutation can cause chamber specific arrhythmia syndromes associated to different functional phenotypes (loss- versus gain-of-function) would represent a significant breakthrough in understanding the role of Kv7.1 in the atrial and ventricular AP.

1.6 Regulation of $I_{Ks}$ by PKA phosphorylation and $\beta$-Adrenergic receptor stimulation

1.6.1 Adrenergic stimulation in the heart and regulation of the funny current and intracellular calcium

$\beta$-adrenergic receptors are a type of G-protein coupled receptors (GPCR) that are typically activated by binding of catecholamines (norepinephrine or epinephrine). There are three subtypes of $\beta$-adrenergic receptors ($\beta_1$, $\beta_2$, and $\beta_3$), and $\beta_1$-adrenergic receptors are the most common subtype expressed in the heart. During sympathetic stimulation, increased cardiac output is a direct result of $\beta_1$-adrenergic receptor activation by binding of norepinephrine or epinephrine. Sympathetic stimulation is up regulated during exercise or emotional stress and causes increases in the heart rate and contractile forces. As a result, the AP duration of ventricular myocytes is shortened to allow proper time for diastolic
filling in between successive beats, and this can be observed by alterations of the QT interval on an ECG.\(^7\)

\(\beta_1\)-adrenergic receptor activation initiates a signaling cascade through \(G_{\text{as}}\)-proteins that activate adenylate cyclase (AC) to increase intracellular levels of cyclic adenosine monophosphate (cAMP).\(^7\)\(^3\), \(^7\)\(^4\) cAMP binds to the regulatory subunits of protein kinase A (PKA), enabling the catalytic subunits of PKA to phosphorylate serine or threonine residues on substrate proteins. PKA function is turned off by a negative feedback system; whereas, PKA activates phosphodiesterases (PDE) to degrade cAMP to its inactive form, AMP.\(^7\)\(^5\) Many ion channels and pumps that control the electrophysiology of the heart are therefore regulated indirectly by cAMP because they are substrates for PKA phosphorylation.

Another important protein regulated directly by cAMP is the hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4) of the pacemaker cells in the sinoatrial node. The regulation of HCN4 by cAMP is different from other ion channels because it does not require PKA-mediated serine or threonine phosphorylation.\(^7\)\(^6\) HCN4 channels are activated at negative or hyperpolarizing membrane potentials and conduct the funny current \((I_f)\) that causes steady depolarization of pacemaker cells.\(^7\)\(^7\) Once a threshold is met, a spontaneous AP will fire in the pacemaker cells to initiate the electrical waveform that controls the coordinated excitation-contraction coupling of cardiomyocytes. When cAMP binds, HCN4 channels activate at more positive potentials, and this increases \(I_f\) during diastole. The increase in \(I_f\) decreases the time it takes a pacemaker cell to
reach threshold to generate a spontaneous AP, and thus, increases the heart rate.\textsuperscript{76, 78}

\(\beta_1\)-adrenergic receptor activation also regulates the control of \(\text{Ca}^{2+}\) transients and contractility of cardiomyocytes. Downstream of cAMP, PKA phosphorylates numerous proteins including L-type Cav channels, ryanodine receptors, and phospholamben to increase the amount of \(\text{Ca}^{2+}\) that enters and is removed from the cytosol during each beat. PKA phosphorylation of L-type Cav channels or ryanodine receptors increases the amplitude of \(I_{\text{Ca,L}}\) and causes an increased amount of \(\text{Ca}^{2+}\) released from the sarcoplasmic reticulum (SR) storage during each beat, respectively.\textsuperscript{79-81} Since more \(\text{Ca}^{2+}\) accumulates in the cytosol during systole in \(\beta_1\)-adrenergic receptor stimulation, more \(\text{Ca}^{2+}\) must also be removed from the cytosol to allow for proper diastolic relaxation. Under basal conditions phospholamben inhibits the function of SR \(\text{Ca}^{2+}\)-ATPase (SERCA), and the main function of SERCA is to extrude cytosolic \(\text{Ca}^{2+}\) into the SR stores. PKA phosphorylation of phospholamben reduces its inhibitory effects on SERCA, and increases the rate of \(\text{Ca}^{2+}\) reuptake into the SR.\textsuperscript{82}

1.6.2 PKA phosphorylates the N-terminus of Kv7.1 to increase \(I_{K_s}\) and prevent ventricular AP prolongation during sympathetic stimulation

During \(\beta_1\)-adrenergic receptor stimulation, repolarizing \(K^+\) currents must also increase to counteract the increases in depolarizing \(I_{\text{Ca,L}}\) in order to prevent AP prolongation. Studies show \(I_{K_s}\) contributes minimally to the ventricular AP at basal levels, but \(I_{K_s}\) amplitude increases during \(\beta_1\)-adrenergic receptor
stimulation significantly increasing its contribution to repolarization.\textsuperscript{11} Voltage-clamp studies show the functional increase of $I_{Kv7.1}$ in response to PKA stimulation requires the coexpression of the KCNE1 $\beta$-subunit and the A-kinase anchoring protein 9 (AKAP9).\textsuperscript{83} Kv7.1 is phosphorylated by PKA on the N-terminus at serine-27 (S27-Kv7.1) following $\beta_1$-adrenergic receptor stimulation, causing an increase in outward $I_{Kv7.1}$. AKAP9 binds to the leucine zipper motif of the C-terminus of Kv7.1 and recruits PKA, protein phosphatases (PP1 and PP2a), and PDE4.\textsuperscript{84} Therefore, the Kv7.1 macromolecular complex can control the local cAMP levels and phosphorylation state of Kv7.1, KCNE1, or AKAP9.\textsuperscript{83-85} The sensitivity of Kv7.1 to PKA stimulation is also influenced by the expression of other KCNE $\beta$-subunits; whereas, voltage-clamp studies coexpressing KCNE2 with WT-Kv7.1 permit the functional increase in $I_{Kv7.1}$, but no increase occurs when KCNE3 is coexpressed.\textsuperscript{86}

1.6.3 PKA regulation of Kv7.1 and LQT1

Risk factors for specific subtypes of LQTS (LQT1, LQT2, or LQT3) are elevated during different states of arousal.\textsuperscript{87,88} Interestingly, cardiac events are typically triggered during exercise when sympathetic tone is elevated in LQT1 patients. For LQT2 or LQT3 patients, cardiac events occur due to sudden stress or during sleep.\textsuperscript{87} These observations suggest the PKA stimulation for LQT1-linked mutations should be studied. Also, mutations in the regulatory proteins of the Kv7.1 macromolecular complex (KCNE1 and AKAP9) are linked to different
subtypes of LQTS (LQT5 and LQT11, respectively), further suggesting the importance of $I_{KS}$-up regulation in response to PKA stimulation.\cite{89,90}

A recent study suggests that an LQT1 mutation (A341V-Kv7.1) generates Kv7.1 channels that are resistant to PKA stimulation (PKA-insensitive), and they conclude that this is likely responsible for the unusually severe clinical phenotype associated with this mutation.\cite{91} Moreover, a separate study shows that patients with PKA-insensitive LQT1 missense mutations located in the cytoplasmic loops (C-loops) of Kv7.1 also associate with an increased risk for life-threatening events.\cite{92} These studies continue to demonstrate the important role that PKA regulation of Kv7.1 channels has in influencing clinical phenotypes.

1.7 Purpose of dissertation

1.7.1 Overview of dissertation project

Research over the last several decades defines LQT1-linked $KCNQ1$ mutations as loss-of-function; whereas, AF-linked $KCNQ1$ mutations generate a gain-of-function phenotype. A clear functional phenotype of a single $KCNQ1$ mutation that predisposes a patient to both LQT1 and AF has not been determined. Furthermore, the existence of concealed LQTS in patients has not been systematically addressed, and understanding why some patients with LQT1-linked $KCNQ1$ mutations do not have prolonged resting QTc intervals remains unclear. Therefore, the overall objectives of this dissertation were:

1) To determine a functional phenotype for $KCNQ1$ mutations linked to LQT1 and early-onset AF
2) Identify molecular mechanism of latent LQT1 phenotypes

1.7.2 Hypothesis and specific aims

The general categorization of LQT1- or AF-linked KCNQ1 mutations as loss- or gain-of-function, respectively, is an oversimplification at best. My overall hypothesis is that studying the regulation of mutant Kv7.1 channels can link functional phenotypes and/or molecular mechanisms with clinical phenotypes.

Specific Aim 1) To test the hypothesis that KCNQ1 mutations linked to LQT1 and AF syndromes generate a unique functional phenotype that predisposes patients to both arrhythmia syndromes.

Specific Aim 2) To test the hypothesis that KCNQ1 mutations linked to latent LQT1 phenotypes primarily generate relatively normally functioning Kv7.1 channels that are resistant to PKA stimulation.

1.7.3 Significance of findings

The findings of this dissertation will help determine the role of Kv7.1 in atrial and ventricular AP repolarization. With these results, I will identify a high-risk functional phenotype for early-onset AF in patients with LQT1-linked KCNQ1 mutations, and distinguish how a relatively benign functional phenotype can predispose patients to latent LQT1. Furthermore, this dissertation will help bridge the gap between understandings in the clinic and laboratory setting to improve mutation-specific risk stratification to better therapeutic interventions of patients with KCNQ1 mutations.
Figure 1.1 A cartoon of one Kv7.1 α-subunit and KCNE1 β-subunit. Together, Kv7.1 α-subunits and KCNE1 β-subunits form a heteromeric channel complex that conducts I_{Ks} in the heart important for the repolarization phase of the human atrial and ventricular AP.
### Table 1.1 Genes associated with specific subtypes of congenital LQTS

<table>
<thead>
<tr>
<th>LQTS type</th>
<th>Gene</th>
<th>Current phenotype</th>
<th>Frequency</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>LQT1</td>
<td>KCNQ1</td>
<td>$I_{Ks}$, ↓ amplitude</td>
<td>~40%</td>
<td>17</td>
</tr>
<tr>
<td>LQT2</td>
<td>KCNH2</td>
<td>$I_{Kr}$, ↓ amplitude</td>
<td>~40%</td>
<td>93</td>
</tr>
<tr>
<td>LQT3</td>
<td>SCN5A</td>
<td>$I_{Na}$, ↑ late current</td>
<td>~10%</td>
<td>94</td>
</tr>
<tr>
<td>LQT4</td>
<td>ANK2</td>
<td>$I_{NCX}$, $I_{NKA}$</td>
<td>Rare</td>
<td>95, 96</td>
</tr>
<tr>
<td>LQT5</td>
<td>KCNE1</td>
<td>$I_{Ks}$, ↓ amplitude</td>
<td>~5%</td>
<td>97</td>
</tr>
<tr>
<td>LQT6</td>
<td>KCNE2</td>
<td>$I_{Kr}$, ↓ amplitude</td>
<td>~3%</td>
<td>98</td>
</tr>
<tr>
<td>LQT7</td>
<td>KCNJ2</td>
<td>$I_{K1}$, ↓ amplitude</td>
<td>Rare</td>
<td>99</td>
</tr>
<tr>
<td>LQT8</td>
<td>CACNA1C</td>
<td>$I_{Ca}$, ↑ late current</td>
<td>Rare</td>
<td>100</td>
</tr>
<tr>
<td>LQT9</td>
<td>CAV3</td>
<td>$I_{Na}$, ↑ late current</td>
<td>Rare</td>
<td>101</td>
</tr>
<tr>
<td>LQT10</td>
<td>SCN4B</td>
<td>$I_{Na}$, ↑ late current</td>
<td>Rare</td>
<td>102</td>
</tr>
<tr>
<td>LQT11</td>
<td>AKAP9</td>
<td>$I_{Ks}$, ↓ amplitude</td>
<td>Rare</td>
<td>103</td>
</tr>
<tr>
<td>LQT12</td>
<td>SCNTA1</td>
<td>$I_{Na}$, ↑ late current</td>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>LQT13</td>
<td>KCNJ5</td>
<td>$I_{KATP}$, ↓ amplitude</td>
<td>Rare</td>
<td></td>
</tr>
</tbody>
</table>
Table 1.2 The Schwartz score criteria for diagnosing LQTS patients^{50}

<table>
<thead>
<tr>
<th>Schwartz score criteria</th>
<th>Points</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ECG findings</strong></td>
<td></td>
</tr>
<tr>
<td>QTc</td>
<td></td>
</tr>
<tr>
<td>≥ 480 ms</td>
<td>3</td>
</tr>
<tr>
<td>460-479 ms (both males and females)</td>
<td>2</td>
</tr>
<tr>
<td>450-459 ms (males)</td>
<td>1</td>
</tr>
<tr>
<td>QTc 4th minute recovery exercise stress test ≥ 480 ms</td>
<td>1</td>
</tr>
<tr>
<td>Torsades de pointes</td>
<td>2</td>
</tr>
<tr>
<td>T-wave alternans</td>
<td>1</td>
</tr>
<tr>
<td>Notched T-wave in 3 leads</td>
<td>1</td>
</tr>
<tr>
<td>Low heart rate for age</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Clinical history</strong></td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td></td>
</tr>
<tr>
<td>Stress induced</td>
<td>2</td>
</tr>
<tr>
<td>Not stress induced</td>
<td>1</td>
</tr>
<tr>
<td>Congenital deafness</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td></td>
</tr>
<tr>
<td>Family member with definite LQTS</td>
<td>1</td>
</tr>
<tr>
<td>Unexplained SCD below age 30 in immediate family member</td>
<td>0.5</td>
</tr>
</tbody>
</table>

- Points are awarded for ECG features only in the absence of an alternative cause (medication, hypokalemia, or exercise).

- Probability of LQTS
  - Low = 1 point
  - Intermediate = 1.5 to 3 points
  - High = ≥ 3.5 points

Copyright © Daniel C. Bartos 2013
Chapter 2
Methods

2.1 Site directed mutagenesis

For KCNQ1 mutations, the appropriate nucleotide changes were engineered in the wild type Kv7.1 (WT-Kv7.1) cDNA cloned in the pcDNA3 plasmid vector using the QuickChange II XL Site Directed Mutagenesis Kit (Stratagene; La Jolla, CA). All Kv7.1 oligonucleotide primers were generated from Integrated DNA Technologies (IDT; Coralville, IA), and the primer sequences are shown in Table I. The integrity of all the constructs was verified by DNA sequencing (Advanced Genetic Technologies Center, AGTC; University of Kentucky, Lexington, KY). Plasmid DNA were replicated and purified using the EndoFree Plasmid Maxi Kit (QIAGEN; Valencia, CA).

2.2 Cell culture and transfection

Human Embryonic Kidney 293 (HEK293) were cultured in Minimum Essential Medium (MEM) supplemented with 10% Fetal Bovine Serum (FBS), non-essential amino acids (NEAA), Penicillin Streptomycin (Pen Strep), and L-Glutamine (Gibco-Invitrogen; Grand Island, NY) and incubated at 37 °C and 5% CO₂. HEK293 cells were transiently transfected using SuperFect transfection reagent (QIAGEN; Valencia, CA) with WT-Kv7.1 or mutant Kv7.1 (3 µg) and KCNEκ (3 µg) (KCNE1, KCNE3, KCNE4 or KCNE5 dependent on the experiment) plasmid DNA. For coexpression studies, cells were transfected with
WT-Kv7.1 (1.5 µg), mutant Kv7.1 (1.5 µg), and KCNEx (3 µg) plasmid DNA. Enhanced Green Fluorescent Protein (GFP) cDNA (0.3 µg) subcloned in pKR5 plasmid vector was also transfected for electrophysiological studies to aid in selection. The SuperFect transfection reagent was washed 3 times with OPTI-MEM reduced serum medium after 3 hours and cells were incubated in normal conditions overnight. After 24-30 hours, cells were removed from culture and analyzed for electrophysiological studies or lysed for further analysis. For perfusion studies or phosphorylation analysis, Kv7.1 (1µg), KCNE1 (1µg), and AKAP9 (6µg) plasmid DNA were cotransfected as described above. AKAP9 and KCNE1 are required for the phosphorylation and functional response of WT-Kv7.1 channels to protein kinase A (PKA) activation.

2.3 Electrophysiology

Functional analyses of whole-cell currents were done using the standard whole-cell patch clamp technique on GFP expressing HEK293 cells. The external recording solution contained (in mM) 137 NaCl, 4 KCl, 1.8 CaCl₂, 1 MgCl₂, 10 glucose, and 10 HEPES (pH 7.4 with NaOH), and an internal pipette solution contained (in mM) 130 KCl, 1 MgCl₂, 4 EDTA, 1 EGTA, 5 MgATP, 10 HEPES (pH 7.2 with KOH). An Axopatch-200B patch clamp amplifier (Axon Instruments; Union City, CA) was used to measure membrane currents and cell capacitance. The uncompensated pipette resistances were 1-2 megaohms (MΩ) and series resistance was compensated between up to 95%. Only cells with stable membrane resistances > 1 gigaohms (GΩ) were studied. The pCLAMP 10
software (Axon Instruments; Union City, CA) was used to generate the voltage protocols, acquire current signals, and for data analyses. Origin 7.0 (Microcal; Northhampton, MA) was used for generating current-voltage (I-V) relations, performing Boltzmann curve fitting, and plotting graphs. The I-V data for the mean tail currents were fit with the following Boltzmann equation:

\[ I = \left( I_{\text{MIN}} - I_{\text{MAX}} / 1 + e^{(V - V_{1/2})/k} \right) + I_{\text{MAX}} \]

where \( I_{\text{MIN}} \) is the minimally activated current (pA/pF); \( I_{\text{MAX}} \) is the maximally activated current (pA/pF); \( V_{1/2} \) is the mid-point potential for half maximal activation (mV); and \( k \) is the slope factor (mV/e-fold change). For all experiments, the holding potential was -80 mV, and the dotted line in figures corresponds to the zero current baseline. The standard voltage protocol used to record currents applied a step-like pulse from -80 mV to 70 mV in 10-mV increments for 5 s, immediately followed by a “tail” pulse for 5 s at -50 mV. Voltage-clamp experiments were performed at 22-23 °C within 1-2 hours of removing the cells from their culture conditions unless noted otherwise.

For voltage-clamp recordings using an atrial action potential (AP) waveform, a waveform was generated from computational simulations of a human atrial AP at 1 Hz.\(^{66, 104}\) For recording using a ventricular AP waveform, a waveform was generated from current clamp recordings of a rabbit ventricular myocyte. The appropriate AP waveform was used as the voltage protocol to acquire current at 1 Hz. The GΩ seal and membrane rupture was obtained at room temperature. Cells were then heated to 37 °C using the TC2BIP Temperature Controller (Cell MicroControls; Norfolk, VA) before currents were recorded.
For perfusion experiments, cells were plated 2 hours prior to recording on 15 mm round glass coverslips coated with 0.01% rat-tail collagen in 0.25% acetic acid. GFP positive cells were recorded with normal extracellular saline as previously described. A voltage protocol described in text was run consecutively every 15 s until maximal current amplitude reached steady-state for each cell. Extracellular bath was replaced via gravity perfusion with fresh extracellular fluid containing forskolin (10 µM) to activate adenylate cyclase + 3-isobutyl-1-methylxanthine (IBMX) (0.2 mM) to inhibit phosphodiesterase activity, collectively increasing intracellular levels of cAMP. The voltage protocol was re-run until the maximal current amplitude reached its new steady-state amplitude.

2.4 Cell lysis

Confluent cell cultures were grown in 60 x 10 mm culture dishes and transfected with 3 µg Kv7.1 and 3 µg KCNE1 cDNA as described above. Cell media was aspirated, and cells were washed 2 times with cell-grade PBS (stored at room temperature). 250 µL of 1% NP-40 solubilization buffer was added to each dish, and cells were scraped to loosen cells from the dish. NP-40 solubilization buffer contained: 7.1 mL ddH$_2$O, 1 mL 10% NP-40, 1 mL 100% glycerol, 0.5 mL 1M Tris-HCl (pH 7.5), 0.3 mL 5 M NaCl, and 0.1 mL 0.5 M EDTA for a total of 10 mL. Protease inhibitor cocktail (Thermo Scientific; Waltham, MA) was added at a concentration of 10 µL per 1 mL of NP-40 solubilization buffer. The cells were subsequently placed in NP-40 solution in a 1.5 mL centrifuge tube.
Prior to Western blotting, cells were placed on ice for immediate use or stored at -80 °C.

2.5 Protein quantification

Cell lysates were utilized immediately or thawed on ice, and they were centrifuged at 13,000 RPM and 4 °C for 15 minutes prior to assaying the protein concentration. The protein concentration was measured using the Bio-Rad DC Protein Assay (Bio-Rad; Hercules, CA). Protein standards were generated by diluting a 2 mg/mL stock of bovine serum albumin, BSA, (Bio-Rad; Hercules, CA) into 1% NP-40 solubilization buffer, and a standard absorbance curve was generated with an R-value ≥ 0.975 for each experiment. The linear regression of the standard absorbance curve was used to calculate the protein concentrations of each lysate sample using a SmartSpec Plus Spectrophotometer (Bio-Rad; Hercules, CA). Equal amounts of cell lysate protein supernatant and SDS PAGE-Laemmli (10% DTT) were heated at 95 °C for 5-10 minutes prior to running samples on acrylamide gels.

2.6 Biotinylation

Confluent cell cultures were grown in 100 x 20 mm culture dishes and individually transfected with 6 µg Kv7.1 and 6 µg KCNE1 cDNA as described above. After 24 hours, cells were washed three times with PBS on ice. Cell surface proteins were isolated using the Pierce Cell Surface Isolation Kit (Pierce; Rockford, IL). The surface proteins were treated with Sulfo-NHS-SS-Biotin
(Pierce; Rockford, IL) for 30 minutes. After the reaction was quenched, cells were washed with refrigerated TBS two times and lysed with NP-40 solubilization buffer (1% SDS). Biotinylated proteins were isolated with NeutrAvidin Agarose (Pierce; Rockford, IL) and eluted on a heat block at 95 °C for 7-10 minutes. Protein concentration was determined similarly to that described above. The cell surface proteins were electrophoresed on a 7% acrylamide gel and transferred to a nitrocellulose membrane. The nitrocellulose membrane was incubated with anti-Kv7.1 (1:3000), anti-Na⁺/K⁺-ATPase (1:2000), or anti-calnexin (1:1000). The Li-cor Odyssey infrared imaging system was used to image the immunoblots. Anti-Kv7.1 was detected using Odyssey Goat anti-Rabbit (1:20,000), and anti-Na⁺/K⁺-ATPase or anti-calnexin were detected using the Odyssey Donkey anti-Mouse (1:20,000).

2.7 Statistical analysis

Data are expressed as the mean ± standard error (SE). For comparisons of two groups, an unpaired Student’s t-test with Welch’s correction (to correct for unequal variances) was run in order to identify whether the data set differed from WT. For recordings involving pharmacological perfusion, a paired Student’s t-test with Welch’s correction was run in order to identify whether the data was different after perfusion compared to baseline recordings. For comparisons of more than two groups, a one-way analysis of variance (ANOVA) with a protected Fisher’s LSD post hoc analysis was performed on data sets to determine which
experimental group(s) differed from one another. (p<0.05 was considered significant)

Any variations or additions to these methods are described in the following chapters in which they pertain.
Table 2.1 Mutagenesis primer sequences for Kv7.1 plasmid DNA

<table>
<thead>
<tr>
<th>Mutation</th>
<th>5’-3’ Forward Sequence</th>
<th>5’-3’ Reverse Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>S27A-Kv7.1</td>
<td>CCG GCG GGG CGC CGC GGG CCT</td>
<td>CAG GCC CGC GGC GCC CCG CCG G</td>
</tr>
<tr>
<td>S27D-Kv7.1</td>
<td>CCC GGC GGG GCG ACG CGG GCC TGG</td>
<td>CCA GGC CCG CGT CGC CCC GCC GGG</td>
</tr>
<tr>
<td>S140G-Kv7.1</td>
<td>TCT GCC TCA TCT TCG GCG TGC TGT CC</td>
<td>GGT GGA CAG CAC GCC GAA GAT GAG G</td>
</tr>
<tr>
<td>V141M-Kv7.1</td>
<td>TGC CTC ATC TTC AGC ATG CTG TCC AC</td>
<td>CGA TGG TGG ACA GCA TGC TGA AGA T</td>
</tr>
<tr>
<td>E160K-Kv7.1</td>
<td>GAC TCT CTT CTG GAT GAA GAT CGT GCT GGT GGT</td>
<td>ACC ACC AGC ACG ATC TTC ATC CAG AAG AGA GTC</td>
</tr>
<tr>
<td>R231C-Kv7.1</td>
<td>CCA TCA GGG GCA TCT GCT TCC TGC AGA TC</td>
<td>GAT CTG CAG GAA GCA GAT GCC CCT GAT GG</td>
</tr>
<tr>
<td>R231H-Kv7.1</td>
<td>CAT CAG GGG CAT CCA CTT CCT GCA GA</td>
<td>GGA TCT GCA GGA AGT GGA TGC CCC T</td>
</tr>
<tr>
<td>I235N-Kv7.1</td>
<td>GCA TCC GCT TCC TGC AGA ACC TGA GGA TG</td>
<td>CAT CCT CAG GTT CTG CAG GAA GCG GAT GC</td>
</tr>
</tbody>
</table>

Copyright © Daniel C. Bartos 2013
Chapter 3

R231C-Kv7.1 is associated with pleiotropic function and expressivity of type 1 long QT syndrome and familial atrial fibrillation

Aspects of this chapter were reported in the *Heart Rhythm Journal*. 2011 Jan:8(1):48-55. PMID: 20850564.

3.1 Introduction

*KCNQ1* encodes the pore-forming α-subunit of the voltage-gated K⁺ channel, Kv7.1. In the heart, Kv7.1 coassembles with KCNE1 β-subunits to conduct the slowly activating delayed rectifier K⁺ current, Iₖₛ.²⁴, ²⁵ Iₖₛ and other K⁺ currents contribute to the repolarization phase of both the atrial and ventricular action potentials (AP). Most notably, hundreds of *KCNQ1* mutations are associated with type 1 long QT syndrome (LQT1) and typically cause a “loss-of-function” in heterologous expression systems. Only a few *KCNQ1* mutations are linked to familial atrial fibrillation, and a gain-of-function phenotype has been implicated to be a consequence of these mutations.⁶³, ⁶⁴

Several groups identified the missense mutation p.Arg231Cys (R231C-Kv7.1) in patients with LQT1, drug-induced long QT syndrome, fetal bradycardia, and persistent AF where QTc prolongation was reported after cardioversion.¹⁰⁵-¹¹⁰ I studied the genotype-phenotype relationships for six unrelated R231C-positive families, five of whom have LQT1 and one family contains four genotype positive individuals with early-onset AF.¹¹¹ This chapter discusses the clinical characteristics of the six families and provides a functional analysis of R231C-
Kv7.1. This is the first study to identify a pleiotropic \textit{KCNQ1} mutation that increases the risk for both LQT1 and early-onset familial AF using genetic and functional analyses.

3.2 Clinical evaluation

3.2.1. Study population and diagnostic criterion

The R231C-Kv7.1 probands had been referred for genetic testing for mutations in LQTS-susceptibility genes. Blood samples were obtained from family members who agreed to genetic evaluation and provided written consent. Patients underwent clinical evaluation and cardiovascular examination, including 12-lead ECG and 24-hour Holter recording. Patients with AF appeared to have “lone AF” because they have normal thyroid function, no hypertension, or structural heart disease as determined by echocardiography. The heart rate corrected QTc was considered prolonged if it was $\geq 450$ ms for males and $\geq 460$ ms for females using the Bazett formula (QTc for R231C-Kv7.1 subjects are given in Table 3.1). The R231C-Kv7.1 subjects with fetal bradycardia were previously reported.$^{105}$

3.2.2 Genetic Analysis

Patient DNA was extracted from peripheral blood leukocytes using standard methods. The probands’ genomic DNA was analyzed for mutations in \textit{KCNQ1}, \textit{KCNH2}, \textit{SCN5A}, and \textit{KCNE1} (genes linked to LQT1, LQT2, LQT3, and LQT5, respectively). The coding regions were amplified using polymerase chain
reaction and sequenced with a 3100 BigDye Terminator v3.1 sequencing kit and ABI PRISM 3100 Genetic Analyzer (Applied Biosystems; Foster City, CA). In the proband of the family associated with familial AF (Family A, subject II:1, Figure 3.1), we tested for mutations in genes previously linked to AF (KCNE2, KCNE3, KCNE5, NPPA, KCNA5, KCNJ2, GJA5, SCN1B, SCN2B, and SCN3B) to determine if there were any additional mutations in AF susceptibility genes. We also compared 21 single nucleotide polymorphisms (SNPs) that alter AF susceptibility among the patients (Families A-F, Figure 3.1).

3.3 Results

3.3.1 R231C is linked to LQT1, fetal bradycardia, and early-onset AF

R231C-Kv7.1 was identified in six probands that presented with a variety of clinical phenotypes (Figure 3.1): one with AF (Family A), three neonates with fetal bradycardia (Families B, D, and E)\(^{105}\), one with a prolonged QTc interval (Family F), and one who is a member of a large LQT1 family previously linked to chromosome 11p15 (Family C).\(^{112}\) Although the proband in Family C (I:2) is asymptomatic, several other family members are symptomatic for LQTS (not shown), including her niece’s baby who was diagnosed with fetal LQTS and bradycardia resulting in intrauterine fetal demise at full term (Stillbirth).\(^{112}\)

In Family A, early-onset AF was diagnosed in the female proband (II:1) at age 33 years, in her father (I:1) at age 18 years, and in two of her brothers (II:3, II:5) at age 30 years and 15 years, respectively. The proband was hospitalized at 33 years of age for persistent AF. After an electrical cardioversion, she has been
treated by sotalol without clinical recurrences until three years after the procedure. She was subsequently diagnosed with paroxysmal AF, and the sotalol treatment was then replaced by flecainide. She is currently asymptomatic. Unlike the other families genotype positive for R231C-Kv7.1, the patients in Family A do not manifest either QTc interval prolongation or syncope. However, patient II:5 experienced ventricular fibrillation four months after cessation of sotalol treatment and died of severe cerebral anoxic damage several days later at age 22 years. One patient in Family A (II:4, brother of proband) is thus far asymptomatic for AF at age 37 years. None of the patients genotype positive for R231C-Kv7.1 with AF have structural heart disease, hypertension, or hyperthyroidism consistent with a clinical diagnosis of lone AF. Furthermore, genetic testing of the proband (II:1) did not reveal any additional mutations in other AF susceptibility genes.

No patient genotype positive for R231C-Kv7.1 in Families B, D, E, and F present with AF. The proband in Family F (now age 57 years) currently receives beta-blocker treatment and underwent defibrillator implantation over three years ago following a severe LQTS-triggered cardiac event. Suspecting the possible contribution of additional genetic factors to AF development, we genotyped all the family members for 21 different SNPs that confer either an increased risk for or are protective of AF susceptibility. We did not find any obvious differences between Family A (AF) and Families B-F (LQT1) that might account for their disparities in clinical phenotypes, except for possibly rs251253, an intergenic SNP located in the region of NKX2-5 gene, which encodes a cardiac-specific
homeobox transcription factor. \textit{Nkrx2-5} is associated with regulating cardiac-specific gene expression, including \textit{NPPA}. \textit{NPPA} has been associated with AF in recent studies and encodes atrial natriuretic peptide (ANP).\textsuperscript{66} Indeed, in Family A, the son (II:4) was the only R231C-Kv7.1 positive family member who did not have AF, but did carry the protective allele. All members carrying R231C-Kv7.1 in the LQT1 families (Families B-F) have the protective allele, with the exception of patient II:2 of Family C (a women who had not manifested AF at age 33 years). This data suggests that R231C-Kv7.1 is primarily linked to LQT1 and fetal bradycardia, but also to a lesser extent, early-onset AF.

3.3.2 \textit{R231C-Kv7.1 conducts large \textit{I}_{K7.1} and causes a gain-of-function}

I determined if R231C-Kv7.1 generates a unique functional phenotype that predisposes patients to both LQT1 and AF. I chose to study the LQT1 mutation, E160K-Kv7.1 as a positive control because like many characterized loss-of-function LQT1 mutants, E160K-Kv7.1 conducts little or no \textit{I}_{K7.1}. I recorded \textit{I}_{K7.1} from HEK293 cells transfected with KCNE1 and E160K-Kv7.1 or R231C-Kv7.1 using the whole-cells patch clamp technique (Figure 3.2A). Currents from nontransfected cells (HEK) and cells expressing E160K-Kv7.1 or R231C-Kv7.1 were measured from a holding potential of -80 mV by applying a step-like pulse from -80 to 70 mV for 5 s in 10-mV increments followed by a “tail” pulse at -50 mV for 5 s. At positive potentials, nontransfected cells generated small, endogenous outward current and little or no tail current. Similar to nontransfected cells, little or no \textit{I}_{K7.1} was measured from cells expressing E160K-Kv7.1. Using
the same voltage protocol, cells expressing R231C-Kv7.1 generated large, constitutive $I_{\text{Kv7.1}}$ that could not be recorded reliably because of apparent changes in local $[K^+]$ (data not shown). I minimized these effects by shortening the duration of the step and tail pulse to 50 ms and 150 ms, respectively, and I applied step pulses from -120 to 70 mV in 10-mV increments to determine the reversal potential of cells expressing R231C-Kv7.1 (Figure 3.2A). The mean peak step current was plotted as a function of voltage to generate the $I$-$V$ relations for cells nontransfected and cells expressing E160K-Kv7.1 or R231C-Kv7.1 (Figure 3.2B). Importantly, for cells expressing R231C-Kv7.1, inward $I_{\text{Kv7.1}}$ was recorded at negative potentials that appeared to reverse around -80 mV suggesting $K^+$ selectivity. Peak tail current was measured upon the immediate start of the tail pulse and the mean peak tail currents were plotted as a function of the step-pulse potential (Figure 3.2C). Large, outward tail $I_{\text{Kv7.1}}$ was measured from cells expressing R231C-Kv7.1 at all potentials suggesting these channels were always activated at -80 mV (constitutive activation). These data show that, although, both E160K-Kv7.1 and R231C-Kv7.1 are linked to LQT1, their effects on $I_{\text{Kv7.1}}$ are dramatically different from one another.

3.3.3 Coexpression of WT- and R231C-Kv7.1 yields a mixed functional phenotype

Since both LQT1 and familial AF follow a dominant inheritance pattern, I determined the effect that coexpression of WT-Kv7.1 has on E160K-Kv7.1 or R231C-Kv7.1. Whole-cell $I_{\text{Kv7.1}}$ was measured from cells expressing KCNE1 with
WT-Kv7.1, WT- and E160K-Kv7.1, or WT- and R231C-Kv7.1 (Figure 3.3A). $I_{Kv7.1}$ were recorded using the 5-s voltage protocol in Figure 3.2A. Cells expressing WT-Kv7.1 conducted $I_{Kv7.1}$ similar to native $I_{Ks}$. Coexpression of WT- and E160K-Kv7.1 generated similar $I_{Ks}$-like $I_{Kv7.1}$, but the amplitude was greatly reduced. Cells coexpressing WT- and R231C-Kv7.1 showed $I_{Kv7.1}$ with a mixed phenotype when compared to cells expressing WT-Kv7.1. At negative potentials, a larger outward $I_{Kv7.1}$ in cells coexpressing WT- and R231C-Kv7.1 was observed, but at positive potentials, the maximal $I_{Kv7.1}$ amplitude in WT-Kv7.1 expressing cells was larger. The mean peak $I-V$ relations measured during the step and tail pulse were plotted for cells expressing WT-Kv7.1, WT- and E160K-Kv7.1, or WT- and R231C-Kv7.1 (Figure 3.3B and 3.3C, respectively). Mean peak tail $I_{Kv7.1}$ were described using a Boltzmann equation to determine $I_{MIN}$, $I_{MAX}$, $V_{1/2}$, and $k$ for $I_{Kv7.1}$ activation (Figure 3.3D-F). Cells coexpressing WT- and R231C-Kv7.1 generated a larger $I_{MIN}$ than cells expressing WT-Kv7.1 suggesting a constitutive component of $I_{Kv7.1}$ persists at all potentials (Figure 3.3D). Cells coexpressing either WT- and E160K-Kv7.1 or WT- and R231C-Kv7.1 had a smaller $I_{MAX}$ than cells expressing WT-Kv7.1 (Figure 3.3D). Furthermore, cells coexpressing WT- and R231C-Kv7.1 had a negative $V_{1/2}$, whereas compared to cells expressing WT-Kv7.1 or WT- and E160K-Kv7.1 (Figure 3.3E). There were no differences in $k$ (Figure 3.3F).

These data suggest that cells coexpressing WT- and R231C-Kv7.1 conduct smaller $I_{MAX}$ than cells expressing either WT-Kv7.1 or R231C-Kv7.1. To determine if this is caused by a reduction in cell surface expression of Kv7.1 channels, a biotinylation assay was performed. No differences in the relative
amount of Kv7.1 expression were observed at the cell surface for cells coexpressing WT- and R231C-Kv7.1 (Figure 3.4).

I, next, measured \( I_{Kv7.1} \) from cells coexpressing KCNE1 with WT-Kv7.1 or WT- and R231C-Kv7.1 to determine if constitutive \( I_{Kv7.1} \) could be observed using the 50-ms voltage protocol used to record the large \( I_{Kv7.1} \) from cells expressing R231C-Kv7.1 (Figure 3.2A). Little or no \( I_{Kv7.1} \) was measured for cells expressing WT-Kv7.1, but cells coexpressing WT- and R231C-Kv7.1 demonstrated a persistent constitutively activated \( I_{Kv7.1} \) (Figure 3.5).

3.3.4 Coexpression of WT- and R231C-Kv7.1 reduced \( I_{Kv7.1} \) at diastolic potentials when recorded using a ventricular AP waveform at 37°C

To this point, these data of R231C-Kv7.1 qualitatively resembles the functional phenotype of KCNQ1 mutations identified in families with AF.\(^{63, 64}\) To determine how R231C-Kv7.1 might contribute to an LQT1 phenotype, I measured \( I_{Kv7.1} \) using a ventricular AP waveform at 37°C pulsed at 1 Hz from nontransfected cells and cells expressing KCNE1 with WT-Kv7.1 or WT- and R231C-Kv7.1 (Figure 3.4D). Representative \( I_{Kv7.1} \) traces were averaged for 60 consecutive pulses for each cell (Figure 3.4D). The small current measured from nontransfected cells is a combination of endogenous HEK current and uncompensated leak/capacitive currents. Cells expressing WT-Kv7.1 or WT- and R231C-Kv7.1 showed large \( I_{Kv7.1} \) that peaked during the plateau phase of the AP waveform. Cells coexpressing WT- and R231C-Kv7.1 did not alter the mean peak \( I_{Kv7.1} \) measured during the AP waveform (WT-Kv7.1 = 371 ± 162 pA/pF, \( n = \)
6; WT- and R231C-Kv7.1 = 335 ± 171 pA/pF, n = 5, p > 0.05). However, cells coexpressing WT- and R231C-Kv7.1 had a smaller fraction of $I_{Kv7.1}$ remaining during repolarization to diastolic potentials (WT-Kv7.1 = 0.14 ± 0.03; WT- and R231C-Kv7.1 = 0 ± 0.03, p < 0.05). We suspect the reduction in $I_{Kv7.1}$ during the repolarization phase might increase the risk for LQT1.

3.3.5 Constitutive $I_{Kv7.1}$ of R231C-Kv7.1 is not dependent of KCNE1 expression

To determine if the constitutive $I_{Kv7.1}$ was dependent on expression of KCNE1 subunits, I measured $I_{Kv7.1}$ from nontransfected cells and cells expressing WT-Kv7.1 or R231C-Kv7.1 using the 5-s voltage protocol described in Figure 3.2 (Figure 3.6A). The mean peak step and tail I-V relations were plotted as a function of the step pulse potential (Figure 3.6B and 3.6C, respectively). Cells expressing WT-Kv7.1 generated small, outward $I_{Kv7.1}$ at positive potentials that demonstrated voltage dependence of activation; whereas, cells expressing R231C-Kv7.1 generated a small, outward tail $I_{Kv7.1}$ at all potentials tested. These data suggest that constitutive activation of R231C-Kv7.1 does not depend on KCNE1 expression.

3.4 Discussion

This is the first study to link a known LQT1 mutation, R231C-Kv7.1, to familial AF and show that an LQT1 mutation can be associated with a gain-of-function phenotype similar to other KCNQ1-mediated AF mutations. Sequencing additional AF-associated genes did not identify additional mutations in the
proband's genotype positive for R231C-Kv7.1. Additionally, twenty-four subjects from the six families genotype positive for R231C-Kv7.1 were genotyped for 21 AF-susceptibility altering SNPs. The only correlation observed was with a protective allele in the *NKK2-5* gene in the LQT1 families, which encodes the cardiac homeobox Nkx2-5 transcription factor.\(^{113}\) The majority of patients genotype positive for R231C-Kv7.1 who did not have AF diagnosed were positive for this SNP suggesting this allele is protective of AF. The only exceptions were a male patient (I:1 of Family A) who was diagnosed with AF and carried the protective allele, and a female patient (II:2 of Family C) who did not have AF and did not have the protective allele. This reiterates the concept that genetic screening for susceptibility alleles is not perfect at predicting clinical outcomes and patient specific differences may contribute to unexplained clinical observations.

In heterologous expression systems, cells coexpressing WT- and R231C-Kv7.1 generates a mixed functional phenotype: a persistent \(I_{\text{Kv7.1}}\) was present at negative potentials (suggesting constitutive activation similar to other *KCNQ1* mutations linked to familial AF)\(^{63,64}\), and a smaller \(I_{\text{MAX}}\) alike *KCNQ1* mutations linked to LQT1.\(^{110}\) To determine the functional consequence of R231C-Kv7.1 on the cardiac AP duration, we generated computational simulations of a human atrial or ventricular AP by altering the \(I_{\text{Ks}}\) component to represent our biophysical findings. We reduced the total number of functional \(I_{\text{Ks}}\) component by 50% and incorporated a minimum open probability of the \(I_{\text{Ks}}\) component to 6.25% for simulations of a human ventricular and atrial AP model (Figure 3.7A and 3.7B,
respectively).\textsuperscript{66, 104, 114} The minimum open probability was set to 6.25% under the assumption that due to random coassembly of Kv7.1 α-subunits, 6.25% (1/16) of the population of I\textsubscript{Ks} channels will be homomeric mutant channels. At 1 Hz cycle frequency, the atrial AP duration was reduced by over 50% (Figure 3.7A), and the ventricular AP duration was reduced by only about 1% (Figure 3.7B). The shortening of atrial AP duration and refactoriness has been known to serve as a substrate to electrical reentry, which can initiate AF.\textsuperscript{55} The modeling suggests R231C-Kv7.1 biophysical properties most likely affect the atrial AP duration in basal conditions because the atrial AP depolarizes to less positive potentials and atrial myocytes have been predicted to have a larger I\textsubscript{Ks} density than ventricular myocytes.\textsuperscript{115} Furthermore, small increases in the open probability of I\textsubscript{Ks} channels preferentially increased the I\textsubscript{Ks} density in atrial myocytes and this may explain the lack of QTc interval shortening in AF patients positive for gain-of-function KCNQ1 mutations.\textsuperscript{63, 65, 66} On the other hand, the lack of ventricular AP prolongation due to a 50% reduction in I\textsubscript{Ks} density is not a surprise because studies have shown that use of I\textsubscript{Ks} blocker (chromanol 293B) in isolated ventricular myocytes does not prolong the ventricular AP duration and I\textsubscript{Ks} density is small in basal conditions.\textsuperscript{116-118} Since LQT1-associated events are typically triggered during situations involving elevation of sympathetic tone such as β-adrenergic activation during exercise, reductions in I\textsubscript{Ks} may be more impactful during these circumstances.\textsuperscript{119}

This was the first study linking a known LQT1 mutation to familial AF. R231C-Kv7.1 generates a bipartite functional phenotype when coexpressed with WT-
Kv7.1 causing an increase in constitutive $I_{\text{Kv7.1}}$ at negative potentials and a reduction in $I_{\text{MAX}}$. I conclude the mixed functional phenotype of R231C-Kv7.1 can predispose patients to LQT1, familial AF, or both.
Figure 3.1 R231C-Kv7.1 genotype positive families. Shown are pedigrees for six families genotype positive for R231C-Kv7.1 (A., B., C., D., E., and F.). Males and females are represented as squares and circles, respectively. The different generations are denoted using Roman numerals, and each individual in a generation is numbered. The genotype/phenotypes are defined in the key. Prolonged QTc interval is defined as ≥450 ms for males or ≥460 ms for females.
Figure 3.2 Cells expressing R231C-Kv7.1 conduct large, constitutive $I_{Kv7.1}$. A. Representative families of whole-cell current recorded from nontransfected cells (HEK, black squares, n = 10), cells transfected with KCNE1 and E160K-Kv7.1 plasmid DNA (E160K, blue open circles, n = 8), or cells transfected with KCNE1 and R231C-Kv7.1 plasmid DNA (R231C, red triangles, n = 20). The voltage protocols used are shown above the current traces. Mean peak step (B) and tail (C) $I_{Kv7.1}$ are plotted as a function of the step pulse potential.
Figure 3.3 Cells coexpressing WT- and R231C-Kv7.1 yield a bipartite functional phenotype. A. Representative families of $I_{Kv7.1}$ measured from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 31), WT- and E160K-Kv7.1 (WT & E160K, blue open circles, n = 13), or WT- and R231C-Kv7.1 (WT &
R231C, red triangles, n = 22). Mean peak step (B) and tail (C) $I_{Kv7.1}$ are plotted as a function of the step pulse potential for cells expressing WT-Kv7.1, WT- and E160K-Kv7.1, or WT- and R231C-Kv7.1. Mean peak tail $I_{Kv7.1}$ were measured at the initiation of the tail pulse and were described using a Boltzmann equation (gray line, Figure 3.2C). The Boltzmann equation calculated the mean $I_{MIN}$ and $I_{MAX}$ (D), $V_{1/2}$ (E), and slope factor, $k$ (F). (* $p < 0.05$ vs. cells expressing WT-Kv7.1)
Figure 3.4 Cell surface expression of R231C-Kv7.1. A. Shown are representative immunoblots of cell surface proteins from cells expressing WT-, E160K-, R231C-, or WT- and R231C-Kv7.1. Also shown is a representative immunoblot of the Whole Cell Lysate (WCL) from non-transfected cells. The top blots show immunolabeling with anti-Kv7.1, the middle blots show immunolabeling with anti-Na\(^+\)/K\(^+\)-ATPase (used as a positive control of cell surface expression), and the bottom blots show immunolabeling with calnexin.
(used as a negative control of an intracellular protein). B. The graph shows the mean ratio of anti-Kv7.1 and anti-Na\(^+\)/K\(^+\)-ATPase densitometries. (n = 4)
Figure 3.5 Cells coexpressing WT- and R231C-Kv7.1 generate constitutively activated $I_{Kv7.1}$ at negative potentials and reduce $I_{Kv7.1}$ during ventricular AP.
**repolarization. A.** Representative families of whole-cell $I_{\text{Kv7.1}}$ recorded from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, $n = 11$) or WT- and R231C-Kv7.1 plasmid DNA (R231C, red triangles, $n = 13$). $I_{\text{Kv7.1}}$ was measured by applying step-like pulses from -120 to -10 mV at 10-mV increments for 50 ms, immediately followed by a tail pulse to -50 mV for 150 ms. The corresponding mean peak step (B) and tail (C) $I_{\text{Kv7.1}}$ are plotted as a function of the step pulse potential. **D.** The ventricular AP waveform used to record current at 37°C is shown. The corresponding current traces were averaged after 60 consecutive pulses (at 1 Hz frequency) from nontransfected cells (HEK, gray line, $n = 4$), and cells transfected with KCNE1 and WT-Kv7.1 plasmid DNA (WT, black line, $n = 5$) or WT- and R231C-Kv7.1 plasmid DNA (WT & R231C, red line, $n = 5$).
Figure 3.6 Cells expressing R231C-Kv7.1 conduct constitutive $I_{\text{Kv7.1}}$ without expressing KCNE1. A. Representative families of whole-cell $I_{\text{Kv7.1}}$ recorded from nontransfected cells (HEK, open diamonds), cells transfected with WT-Kv7.1 plasmid DNA (WT, black squares) or cells transfected with R231C-Kv7.1 plasmid DNA (R231C, open red triangles) are shown. The voltage protocol used to measure the $I_{\text{Kv7.1}}$ was similar to the 5-s voltage protocol used in Figure 3.2. The mean peak step (B) and tail (C) $I_{\text{Kv7.1}}$ are plotted as a function of the step voltage for nontransfected cells, cells expressing WT-Kv7.1 or cells expressing R231C-Kv7.1.
Figure 3.7 Computational simulations of human atrial and ventricular AP.

Computational model of a human atrial (A) or ventricular (B) AP waveform pulsed at 1 Hz and the corresponding $I_{Ks}$ density and channel open probability is displayed. Blue traces represent control $I_{Ks}$, and red traces represent simulations in which the $I_{Ks}$ component was altered to incorporate a 50% reduction in the number of functional channels and a minimum open probability of 6.25%. (The computational simulations were performed in collaboration with Dr. Don E. Burgess)
Table 3.1 QTc values for patients genotype positive for R231C-Kv7.1. QTc interval was calculated using Bazett’s formula\textsuperscript{46}:

\[ QTc = \frac{QT}{\sqrt{RR}} \]

LQT1 was defined as having a QTc interval ≥ 450 ms for males and ≥ 460 ms for females.

<table>
<thead>
<tr>
<th>Family:subject</th>
<th>QTc (ms)</th>
<th>AF</th>
<th>LQT1</th>
</tr>
</thead>
<tbody>
<tr>
<td>A I:1</td>
<td>382</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>A II:1</td>
<td>417</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>A II:3</td>
<td>368</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>A II:4</td>
<td>398</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>A II:5</td>
<td>407</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>B I:2</td>
<td>442</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>B II:1</td>
<td>425</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>B II:2</td>
<td>424</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>B II:3</td>
<td>503</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>C II:2</td>
<td>486</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>D II:1</td>
<td>432</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>D III:1</td>
<td>527</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E II:1</td>
<td>460</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E II:2</td>
<td>480</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E III:1</td>
<td>545</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>E III:2</td>
<td>476</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>F I:2</td>
<td>471</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Copyright © Daniel C. Bartos 2013
Chapter 4

R231H-Kv7.1 provides direct evidence of a KCNQ1 mutation causing early-onset atrial fibrillation

Aspects of these data presented in this chapter were published in the Journal of Cardiovascular Electrophysiology. Epub 2012 Dec 11. PMID: 23350853.

4.1 Introduction

AF is the most common sustained cardiac arrhythmia syndrome, and patients with AF may experience palpitations, syncope, congestive heart failure, and an increased risk of stroke.\(^{120-124}\) Familial reports of AF have been studied for over 70 years, but understanding the direct genetic linkage has been difficult to interpret for clinician scientists.\(^62\) Although rare, KCNQ1 mutations have recently been increasingly associated to familial AF in multigenerational families.\(^{63-66, 111}\) All of these mutations have only been linked to familial AF in one patient or one family each, and several mutations have been identified in additional families associated with LQT1 or indicated as SNPs in the general population.\(^{111, 125}\) Identifying familial AF in multiple unrelated families would represent a significant finding in understanding the genetic and molecular role of KCNQ1 to familial AF.

In the previous chapter, we described an LQT1 mutation (p.Arg231Cys or R231C-Kv7.1) that caused a gain-of-function phenotype by producing constitutive $I_{Kv7.1}$ at negative potentials; however, it also caused a loss-of-function by decreasing the $I_{MAX}$ by > 50% when co-expressed with wild-type (WT-Kv7.1). Clinical phenotypes from six different families suggested that R231C-Kv7.1
conferred a higher risk for LQT1, because five of the six genotype positive families have LQT1 without AF and only one family has familial early-onset AF without LQT1. In this chapter, we discuss the identification of a similar missense mutation, p.Arg231His (R231H-Kv7.1), in five unrelated families with a history of familial early-onset AF.\textsuperscript{126} Previous reports linked R231H-Kv7.1 to LQT1 and more recently to early-onset AF.\textsuperscript{70,127} The purpose of this chapter is to identify a potential mechanism for the high incidence of early-onset AF in patients genotype positive for R231H-Kv7.1 using functional and computational analysis.

4.2 Results

4.2.1 Genetic screening

We identified five unrelated probands who are genotype positive for the LQT1 mutation R231H-Kv7.1 (Figure 4.1). The proband in Figure 4.1A was reported previously.\textsuperscript{70} The Institutional Ethics Committees approved the respective protocols for research-based genetic analysis for patients with LQTS and the patients provided informed consent before either research testing or clinical testing with one of the commercially available LQTS genetic tests. Genomic DNA was performed using standard methods. The DNA of probands from families A, C, and E were negative for additional mutations when screened in other autosomal dominant AF-related genes (\textit{KCNH2}, \textit{SCN5A}, \textit{KCNJ2}, \textit{KCNE1}, \textit{KCNE2}). The proband in families B and D were negative for mutations in \textit{SCN5A}. 

54
4.2.2 R231H-Kv7.1 is prevalent among families with a history of familial early-onset atrial fibrillation

R231H-Kv7.1 was initially reported in a single patient with LQT1, and subsequently in a one-year-old female patient suspected of having LQT1. Although, the patient data for these individuals are limited, the latter patient has early-onset AF and only a borderline QTc interval of 480 ms (Figure 4.1A). Unfortunately, the current status of this patient and other family members are not available.

We now report the clinical phenotypes for four additional families genotype positive for R231H-Kv7.1. The probands were referred for genetic testing because they are symptomatic for atrial and ventricular arrhythmias (Figure 4.1B-E), including sudden cardiac arrest while sleeping (Family B), fetal bradycardia (Family C), or familial AF (Family D and E).

In family B, the proband is a 20 year-old male (II:1) who presented with ventricular fibrillation while sleeping. He was successfully resuscitated, but was subsequently diagnosed with early-onset AF. The patient received two unsuccessful direct current cardioversions (DCCVs) and underwent one unsuccessful pulmonary vein isolation. Sinus rhythm was maintained for a short time with amiodarone, but he is currently in persistent AF and receiving β-blocker therapy. The patient’s mother (I:2) is positive for R231H-Kv7.1, was diagnosed with early-onset AF at 6 years of age, and has received two unsuccessful DCCVs. Following the index patient’s cardiac arrest, his sister (II:2, age 24) and brother (III:3, age 16), were also found to be genotype positive for R231H-Kv7.1 and in
The brother (but not the sister) was successfully treated with DCCV. All members of family B that are positive for R231H-Kv7.1 have AF and normal QTc intervals.

The proband in family C (III:1) was born by cesarean section at gestational age 32 weeks prompted by fetal bradycardia. Since then, he has had multiple ECGs and no abnormalities have been observed. The proband’s mother (II:2), maternal grandmother (I:2), and brother (III:2) all tested positive for R231H-Kv7.1, and all have normal QTc intervals. Both the mother and maternal grandmother were diagnosed with early-onset AF at 16 years of age. Currently, the brother is asymptomatic.

In family D, early-onset AF was diagnosed in the female proband (III:1) at age 14, and in her mother (II:2), maternal aunt (II:3), and maternal uncle (II:4). The proband underwent successful DCCV for one year but the patient is now in AF. Holter monitor showed multifocal ventricular ectopy with bigeminy, trigeminy, and couplets, and although her resting QTc interval was normal, epinephrine testing unmasked QTc interval prolongation using the Shimizu protocol. The proband’s sister (III:2) is also genotype positive for R231H-Kv7.1. Holter monitoring of the sister also showed frequent ventricular ectopy and a normal QTc interval, but she is thus far asymptomatic for AF. Although not genetically tested, the patient’s mother and maternal aunt both died suddenly while sleeping at the ages of 60 and 55 years, respectively.

The final proband of family E (I:2) first developed paroxysmal early-onset AF at age 32 and has experienced 10 episodes of AF over the last 14 years with
each event requiring DCCV to restore normal sinus rhythm. On several occasions, ECG or echocardiogram testing suggested that this patient has a normal QTc interval, heart structure, and heart function. The proband was adopted and has no documented family history of AF from previous generations. Two out of three children were found genotype positive for R231H-Kv7.1, and her youngest daughter was negative. Her son (II:1) developed paroxysmal early-onset AF at age 13 with at least 2 episodes, experienced significant bradycardia, and has a prolonged QTc interval. The eldest daughter (II:2) developed early-onset AF at age 16 with a normal QTc interval. Both AF-bearing children required DCCV to regain normal sinus rhythm. Overall, the mean QTc interval value for the fourteen patients genotype positive for R231H-Kv7.1 among the five unrelated families is in the normal range (mean 444 ± 20 (SD) ms).

4.2.3 Cells coexpressing WT- and R231H-Kv7.1 increase $I_{Kv7.1}$ at negative membrane potentials, but do not decrease maximally activated $I_{Kv7.1}$

The clinical data are the first to link a single KCNQ1 mutation to familial early-onset AF in multiple unrelated families. The high penetrance of AF within individual families suggests this mutation might generate a unique functional phenotype that conveys a high risk for early-onset AF. To test this, I coexpressed KCNE1 with WT-Kv7.1, R231H-Kv7.1, or WT- and R231H-Kv7.1 in HEK293 cells and recorded macroscopic $I_{Kv7.1}$ by applying the 5-s voltage protocol described in Chapter 3 (Figure 4.2). The peak $I_{Kv7.1}$ recorded during the step pulse or at the initiation of the tail pulse was plotted as a function of the step pulse potential to
generate step and tail I-V relations (Figure 4.2B and 4.2C, respectively). The peak tail I-V relations were described with a Boltzmann equation for cells expressing WT-Kv7.1 or WT- and R231H-Kv7.1 (Figure 4.2C). Cells expressing R231H-Kv7.1 conducted \( I_{\text{Kv7.1}} \) that was activated at all potentials tested and showed little or no voltage dependence of activation. An intermediate phenotype was observed for cells coexpressing WT- and R231H-Kv7.1; whereas, they generated a larger \( I_{\text{MIN}} \) than cells expressing WT-Kv7.1 suggesting a constitutive component of \( I_{\text{Kv7.1}} \) was present at negative potentials (Figure 4.2D). Also, compared to cells expressing WT-Kv7.1, cells coexpressing WT- and R231H-Kv7.1 did not alter \( I_{\text{MAX}} \) (Figure 4.2E), had a more negative \( V_{1/2} \) (Figure 4.2F), and a larger \( k \) (Figure 4.2G).

To more clearly determine whether cells coexpressing WT- and R231H-Kv7.1 have constitutively activated \( I_{\text{Kv7.1}} \) at -80 mV, I applied 50 ms step pulses from -120 to -50 mV in 10-mV increments followed by a 150 ms tail pulse to -50 mV (Figure 4.3A). The mean peak step or tail I-V relations were generated by plotting the peak \( I_{\text{Kv7.1}} \) measured at the start of each pulse as a function of the step pulse potential (Figure 4.3B and 4.3C, respectively). Almost no step or tail \( I_{\text{Kv7.1}} \) was observed for cells expressing WT-Kv7.1, but cells coexpressing WT- and R231H-Kv7.1 generated inward and outward step current that reversed around -80 mV. Additionally, cells coexpressing WT- and R231H-Kv7.1 also generated outward tail \( I_{\text{Kv7.1}} \) at all potentials tested. These data clearly demonstrate that cells coexpressing WT and R231H-Kv7.1 have constitutively activated \( I_{\text{Kv7.1}} \) at -80 mV,
but cells expressing WT-Kv7.1 do not. Biotinylation experiments showed the cell surface expression of WT-Kv7.1 and R231H-Kv7.1 was not different (Figure 4.4).

4.2.4 Cells coexpressing WT- and R231H-Kv7.1 increase $I_{Kv7.1}$ when recorded using an atrial AP waveform

I determined if cells coexpressing WT- and R231H-Kv7.1 increased $I_{Kv7.1}$ recorded using a human atrial AP waveform. To do this, I voltage-clamped cells expressing KCNE1 with WT-Kv7.1 or WT- and R231H-Kv7.1 at 37 °C (to mimic physiological temperature) and pulsed the cells with an atrial AP waveform at a frequency of 1 Hz (Figure 4.5A). The atrial AP waveform was generated from computational simulations of a human atrial AP pulsed at 1 Hz.66,104 I averaged the $I_{Kv7.1}$ recorded from 50 consecutive pulses. Pulsing cells expressing WT-Kv7.1 activated a small amount of $I_{Kv7.1}$, but cells coexpressing WT- and R231H-Kv7.1 showed a large outward $I_{Kv7.1}$ (Figure 4.5B).

4.2.5 R231H-Kv7.1 preferentially shortens the atrial AP duration in computational simulations

We performed simulations of a computational model of a human atrial AP to determine the effect R231H-Kv7.1 has on atrial AP duration over a wide range of cycle lengths.66,107 To mimic the biophysical properties of R231H-Kv7.1, we altered the $I_{Ks}$ component to maintain an open probability of 6.25%, representing constitutive activation at negative potentials. This is the fraction of $I_{Ks}$ that is predicted to be constitutively active based on random coassembly of WT- and
R231H-κv7.1 α-subunits, and it coincides with the experimental data. This is similar to the simulations discussed in the previous chapter, except we do not reduce the number of I_{Ks} channels; therefore, we are not reducing the maximal I_{Ks}. We did, however, perform separate simulations that completely lacked the I_{Ks} component to compare the effects a loss-of-function KCNQ1 mutation has on the atrial AP duration. Comparable to before, the small increase in open probability of the I_{Ks} component to 6.25% at rest will cause a range of shortening ~ 40 - 60% of the atrial AP duration at all cycle lengths tested (Figure 4.6B). On the other hand, the simulation that completely lacked I_{Ks} displayed only a minor (< 10%) prolongation in the atrial AP duration.

4.2.6 Cells coexpressing KCNE3 and R231H-Kv7.1 decrease voltage-dependent gating of activation

In both the human atria and ventricles, Kv7.1 has been suggested to interact with other KCNE β-subunits (KCNE2-5) that can alter the biophysical properties of I_{Ks}. KCNE2, KCNE4, and KCNE5 are all inhibitory, but KCNE3 increases I_{Kv7.1} similar to KCNE1 and stabilizes the Kv7.1 voltage-sensor in a semi-conductive state to generate a constitutive I_{Kv7.1}, which can be activated to a fully conductive state upon membrane depolarization. Since, WT-Kv7.1 is positively regulated by KCNE3, I expressed KCNE3 with WT-Kv7.1 or R231H-Kv7.1 to determine how KCNE3 regulates the function of R231H-Kv7.1. I_{Kv7.1} were measured by applying step pulses from -80 to 70 mV in 10-mV increments for 2 s, followed by a tail pulse for 2 s at -50 mV for cells expressing KCNE3 with
WT-Kv7.1 or R231H-Kv7.1 (Figure 4.7A). The mean peak $I_{\text{Kv7.1}}$ recorded during the step pulse (Figure 4.7B) or at the initiation of the tail pulse (Figure 4.7C) was plotted as a function of the step pulse potential to generate $I$-$V$ relations. Similar to previous recordings, the mean peak tail $I$-$V$ relations were described with a Boltzmann equation to determine $I_{\text{MIN}}$ (Figure 4.7D), $I_{\text{MAX}}$ (Figure 4.7E), $V^{1/2}$ (Figure 4.7F), and $k$ (Figure 4.7G). Cells expressing R231H-Kv7.1 conducted a minimally activated $I_{\text{Kv7.1}}$ comparable to cells expressing WT-Kv7.1, but the $I_{\text{MAX}}$ was much smaller (Figure 4.7D and 4.7E, respectively). Coexpressing KCNE3 with R231H-Kv7.1 yielded a seemingly opposite result as to what was seen in cells expressing KCNE1 (Figure 4.2). Cells expressing KCNE1 with R231H-Kv7.1 conducted primarily maximally activated $I_{\text{Kv7.1}}$ ($I_{\text{MAX}}$); whereas expressing KCNE3 with R231H-Kv7.1 elicited primarily minimally activated $I_{\text{Kv7.1}}$ ($I_{\text{MIN}}$). In both instances, the voltage dependence of activation is almost completely disrupted. I also tested the inhibitory effects of KCNE4 and KCNE5, but the corresponding currents were small and I did not detect any differences between $I_{\text{Kv7.1}}$ measured from cells expressing WT-Kv7.1 or R231H-Kv7.1 (data not shown).

4.2.7 Parallel functional analysis of AF-linked KCNQ1 mutations that elicit constitutive activation of Kv7.1

Thus far, eight KCNQ1 mutations are linked to AF, but only four have been shown to increase the constitutive activation of $I_{\text{Ks}}$.63-66, 71, 111, 126, 133 As with R231C-Kv7.1 and R231H-Kv7.1, each mutation equates with a different clinical
phenotype among genotype positive families. Therefore, I sought to determine if the KCNQ1 mutations that cause constitutive activation of Kv7.1 (S140G-Kv7.1, V141M-Kv7.1, R231C-Kv7.1, and R231H-Kv7.1) had distinct functional phenotypes when compared side-by-side. I coexpressed KCNE1 with WT-Kv7.1, WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1, or WT- and R231H-Kv7.1 and recorded $I_{K_{v7.1}}$ by applying the 5-s voltage protocol previously described in chapter 3 (Figure 4.8A). The mean peak step (Figure 4.8B) and tail (Figure 4.8C) I-V relations were plotted as a function of the step pulse potential. The peak tail I-V relations were described with a Boltzmann equation for cells expressing WT-Kv7.1, WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1 or WT- and R231H-Kv7.1 (Figure 4.8C). All cells coexpressing WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1, or WT- and R231H-Kv7.1 conducted a $I_{MIN}$ that was larger than cells coexpressing WT-Kv7.1, suggesting they all generate a similar amplitude of constitutively active $I_{K_{v7.1}}$ at negative potentials (Figure 4.8D). Interestingly, cells coexpressing WT- and S140G-Kv7.1, WT- and V141-Kv7.1, or WT- and R231C-Kv7.1 had an $I_{MAX}$ that was less than WT-Kv7.1 expressing cells, but cells coexpressing WT- and R231H-Kv7.1 did not (Figure 4.8E). All cohorts of cells caused a negative shift in the $V_{1/2}$ compared to cells expressing WT-Kv7.1 (Figure 4.8F). When compared to each other, cells coexpressing WT- and R231C-Kv7.1 had a smaller $I_{MAX}$ than cells expressing WT- and R231H-Kv7.1. These data were consistent with our previous reports that suggested that R231C-Kv7.1 reduces $I_{MAX}$, but R231H-Kv7.1, does not.$^{111, 126}$
4.3 Discussion

In this chapter we report five unrelated families genotype positive for R231H-Kv7.1, and all five families have a history of familial early-onset AF. This is the first study to identify a single KCNQ1 variant in separate families with familial AF. In vitro analyses demonstrated that R231H-Kv7.1 primarily caused a gain-of-function phenotype by causing constitutively active \( I_{Ks} \) at negative potentials. Unlike R231C-Kv7.1, R231H-Kv7.1 did not reduce \( I_{MAX} \).

\( I_{Kv7.1} \) recorded from cells coexpressing WT- and R231H-Kv7.1 were much larger than cells expressing WT-Kv7.1 using an atrial AP waveform suggesting that heteromeric \( I_{Ks} \) channels will lead to a shortening of the atrial AP. Similarly to the previous chapter, we showed using atrial AP simulations that increasing the open probability of \( I_{Ks} \) channels by 6.25% will cause ~ 50% shortening of the atrial AP duration. This is expected to decrease the distance an electrical impulse travels in one refractory period (cardiac wavelength). If the cardiac wavelength becomes shorter than the path-length of the electrical impulse, then multiple reentry circuits can develop to induce fibrillation.\(^{55, 69, 134}\) The computational modeling of an atrial AP across a range of cycle lengths suggests that the shortening of the atrial AP duration is greater as the cycle length is increased (Figure 4.6B). Interestingly, analogous functional effects of increasing \( I_{Ks} \) at negative potentials do not cause abnormal shortening of the ventricular AP duration.\(^{111}\)

One of the reasons R231H-Kv7.1 causes constitutively activated \( I_{Kv7.1} \) may be due to its positioning. R231H-Kv7.1 disrupts a highly conserved arginine residue
in the Kv7.1 S4 voltage sensor transmembrane segment. Like other voltage
gated K\(^+\) channels, the S4 of Kv7.1 is responsible for sensing membrane
potential changes, and depolarization drives S4 towards the extracellular side of
the plasma membrane to stabilize the maximally activated state.\(^8\) Our data
suggests that R231H-Kv7.1 stabilized the maximally activated state when
expressed with KCNE1 (Figure 4.2C). In contrast to KCNE1, KCNE3 modulates
WT-Kv7.1 to favor a partially conducting “closed” state rather than a
nonconducting closed state at negative membrane potentials, and upon
membrane depolarization Kv7.1 further activates to a new more conductive state
(Figure 4.7C).\(^{29, 132}\) Surprisingly, cells expressing KCNE3 and R231H-Kv7.1
stabilized the partially conducting closed state, but not the maximally activated
state (Figure 4.7C). This suggests that R231H-Kv7.1 causes S4 immobilization in
a KCNE1 or KCNE3 dependent manner. Coexpression of R231H-Kv7.1 with
KCNE1 immobilizes the S4 to the maximally activated position, and coexpression
of KCNE3 immobilizes S4 into its minimally activated position.

In direct comparison to other AF-linked KCNQ1 mutations to WT-Kv7.1, I
found R231H-Kv7.1 is the only mutation that does not reduce \(I_{MAX}\) when
coexpressed with WT-Kv7.1 (Figure 4.8C). This is not surprising because many
patients genotype positive for S140G-Kv7.1 or R231C-Kv7.1 have prolonged
QTc interval or are diagnosed with LQT1.\(^{63, 111}\) On the other hand, the patient
genotype positive for V141M-Kv7.1 did not have QT interval prolongation, but
coexpression of WT- and V141M-Kv7.1 did reduce \(I_{MAX}\).\(^{64}\) The discrepancy in
these results could be due to the fact that V141M-Kv7.1 was discovered in only one patient as a de novo mutation.

In summary, R231H-Kv7.1 is different than R231C-Kv7.1 and other AF-linked KCNQ1 mutations, and R231H-Kv7.1 causes a high-risk functional phenotype for early-onset AF. The prevalence of the R231H-Kv7.1 mutation as a cause of early-onset AF in large cohorts remains unknown (and likely represents a small number). Additionally, some AF-susceptibility genes were not screened in these patients. However, the presence of this rare KCNQ1 variant in multiple kindreds with appropriate segregation and AF, the biophysical findings observed, and the known association of KCNQ1 with familial AF strongly support a contribution of R231H-Kv7.1 to AF vulnerability. R231H-Kv7.1 provides a strong molecular link to the manifestation of early-onset AF in unrelated families. Our studies indicate that R231H-Kv7.1 likely increases the amount of $I_{Ks}$ during the atrial AP to dramatically shorten its duration. I conclude genetic variants that shorten atrial refractoriness will present a high risk for interfamilial early-onset AF.
Figure 4.1 R231H-Kv7.1 confers a high risk for early-onset AF. Pedigrees of five non-related families (A., B., C., D., and E.) genotype positive for R231H-Kv7.1 are identified. Individual males or females are represented as squares or circles, respectively; each generation is denoted by a Roman numeral; and the
patients’ clinical phenotypes/genotypes are defined in the key. Prolonged QTc interval is defined as ≥ 450 ms for males or ≥ 460 ms for females.
Figure 4.2 Cells coexpressing WT- and R231H-Kv7.1 do not reduce $I_{\text{MAX}}$. A.

Representative families of $I_{\text{Kv7.1}}$ measured from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, $n = 18$), R231H-Kv7.1 (R231H, blue filled triangles, $n$
= 11), or WT- and R231H-Kv7.1 (WT & R231H, blue open triangles, n = 15). Mean peak step (B) and tail (C) \( I_{Kv7.1} \) are plotted as a function of the step pulse potential for cells expressing WT-Kv7.1, R231H-Kv7.1, or WT- and R231H-Kv7.1. Peak tail \( I_{Kv7.1} \) were measured at the initiation of the tail pulse and the tail I-V relations of cells expressing WT-Kv7.1 or WT- and R231H-Kv7.1 were described using a Boltzmann equation (gray line, Figure 4.2C). The Boltzmann equation calculated the mean \( I_{MIN} \) (D), \( I_{MAX} \) (E), \( V\frac{1}{2} \) (F), and slope factor, \( k \) (G). (* \( p < 0.05 \) vs. cells expressing WT-Kv7.1)
Figure 4.3 Cells coexpressing WT- and R231H-Kv7.1 generate constitutive $I_{Kv7.1}$ similar to R231C-Kv7.1. A. Representative families of whole-cell $I_{Kv7.1}$ recorded from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, $n = 15$) or WT- and R231H-Kv7.1 plasmid DNA (WT & R231H, blue open triangles, $n = 11$). $I_{Kv7.1}$ was measured by applying step-like pulses from -120 to -50 mV at 10-mV increments for 50 ms, immediately followed by a tail pulse to -50 mV for 150 ms. The corresponding mean peak step (B) and tail (C) $I_{Kv7.1}$ are plotted as a function of the step pulse potential.
Figure 4.4 R231H-Kv7.1 does not alter cell surface expression. A. Shown are representative immunoblots of cell surface proteins isolated via biotinylation from cells expressing WT-Kv7.1 or R231H-Kv7.1. Also shown is a representative immunoblot of the Whole Cell Lysate (WCL) from non-transfected HEK293 cells. The top blots show immunolabeling with anti-Kv7.1, the middle blots show immunolabeling with anti-Na⁺/K⁺-ATPase (used as a positive control of cell surface expression), and the bottom blots show immunolabeling with calnexin (used as a negative control of an intracellular protein). B. The graph shows the mean ratio of anti-Kv7.1 and anti-Na⁺/K⁺-ATPase densitometries. (n = 4)
Figure 4.5 Coexpressing WT- and R231H-Kv7.1 increases $I_{Kv7.1}$ when measured using an atrial AP waveform at physiological temperature. A. Shown are representative $I_{Kv7.1}$ traces from cells expressing WT-Kv7.1 (WT, black line, n = 10) or WT- and R231H-Kv7.1 (WT & R231H, blue line, n = 11) recorded using the atrial AP waveform at 37 °C. B. The mean peak $I_{Kv7.1}$ (± SE) measured during the plateau phase of the atrial AP is plotted in the bar graph (* p < 0.05).
Figure 4.6 R231H-Kv7.1 is predicted to shorten the atrial AP duration. A. Shown is a computation model of an atrial AP waveform at a cycle length of 1000 ms (indicated by the arrow, Figure 4.6B) for simulations involving control $I_{Ks}$ (black trace), a mutation increasing the open probability of $I_{Ks}$ by 6.25% (R231H-Kv7.1, blue trace), and a mutation causing a loss-of-function in $I_{Ks}$ (red trace). B. Plotted is the steady-state AP duration to 90% repolarization (APD90) as a function of cycle length for atrial AP simulations with control $I_{Ks}$ (black squares), a mutation causing an increase in 6.25% open probability (R231H-Kv7.1, blue
open triangles), and a loss-of-function of $I_{Ks}$ (open red circles). (These data were obtained in collaboration with Dr. Don E. Burgess)
Figure 4.7 Coexpression of R231H-Kv7.1 and KCNE3 decreases maximally activated $I_{\text{Kv7.1}}$. A. Shown are representative $I_{\text{Kv7.1}}$ from cells expressing KCNE3 with WT-Kv7.1 (WT & KCNE3, black squares, n = 17) or R231H-Kv7.1 (R231H &
KCNE3, blue triangles, n = 18) recorded from the voltage protocol situated above. Tail $I_{Kv7.1}$ are enlarged in the inset (scale bars represent 0.2 nA and 10 ms). Mean peak step (B) and tail (C) $I_{Kv7.1}$ are plotted as a function of the step pulse potential for cells expressing KCNE3 and WT-Kv7.1 or R231H-Kv7.1. Mean peak tail $I_{Kv7.1}$ were measured at the initiation of the tail pulse and were described using a Boltzmann equation (gray line, Figure 4.7C). The Boltzmann equation calculated the mean $I_{\text{MIN}}$ (D), $I_{\text{MAX}}$ (E), $V_{1/2}$ (F), and slope factor, $k$ (G). (* p < 0.05 vs. cells expressing WT-Kv7.1)
Figure 4.8 Analysis of AF-linked KCNQ1 mutations. A. Representative families of $I_{\text{Kv7.1}}$ measured from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 14), WT- and S140G-Kv7.1 (WT & S140G, wine open circles,
n = 15), WT- and V141M-Kv7.1 (WT & V141M, green diamond, n = 9), WT- and R231C-Kv7.1 (WT & R231C, red triangles, n = 11), or WT- and R231H-Kv7.1 (WT & R231H, blue open triangles, n = 10). Mean peak step (B) and tail (C) $I_{Kv7.1}$ are plotted as a function of the step pulse potential for cells expressing WT-Kv7.1, WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1 or WT- and R231H-Kv7.1. Mean peak tail $I_{Kv7.1}$ were measured at the initiation of the tail pulse and were described using a Boltzmann equation (gray line, Figure 4.8C). The Boltzmann equation calculated the mean $I_{MIN}$ (D), $I_{MAX}$ (E), $V_{1/2}$ (F), and slope factor, $k$ (G). (* $p < 0.05$ vs. cells expressing WT-Kv7.1 or otherwise labeled comparisons)
Chapter 5

PKA insensitive Kv7.1 mutants identify with latent type 1 long QT syndrome

5.1 Introduction

The diagnosis of LQTS can be difficult to assess due to the estimation that up to 40% of patients genotype positive for LQTS related mutations have a normal to borderline resting QTc interval, referred to as concealed LQTS.\(^5^3\),\(^1^3^5\) In recent years, clinical diagnostic tools (exercise or epinephrine stress testing) have been used to unmask latent LQTS phenotypes in patients with concealed LQTS (otherwise known as latent LQTS). These diagnostic tools are useful for distinguishing between susceptible and ostensibly normal patients. Notably, exercise treadmill stress testing reliably predicts latent LQT1.\(^5^3\) Latent LQT1 patients have QTc intervals that do not shorten during peak exercise, and their QTc intervals show abnormal prolongation during the recovery phase after exercise.

During exercise, elevated levels of epinephrine and norepinephrine activate β-adrenergic receptors to increase \(I_{Ks}\) to regulate the ventricular AP duration.\(^7^3\),\(^8^3\),\(^1^3^6\) β-adrenergic receptor activation increases \(I_{Ks}\) by stimulating PKA phosphorylation of Kv7.1 at S27. The PKA-induced increase in \(I_{Ks}\) requires the \(I_{Ks}\)-macromolecular complex, which includes KCNE1 and AKAP9.\(^8^3\),\(^1^3^7\) The important role that \(I_{Ks}\) has in regulating the AP duration with exercise is exemplified as most LQT1-related events are triggered in patients exercising or swimming.\(^1^3^8\),\(^1^3^9\) Studies recently suggest that LQT1 mutations which prevent the
PKA-induced increase in \( I_{K_s} \) might associate with a high-risk for life threatening events.\(^83,91,92\)

In this chapter, we focus on the LQT1-linked mutation p.Iso235Asn (I235N-Kv7.1) because we found ten out of ten patients with I235N-Kv7.1 tested positive for latent LQT1.\(^140\) This suggests that I235N-Kv7.1 confers a high-risk for latent LQT1. Each patient has a normal resting QTc interval, but showed exaggerated QTc interval prolongation during the recovery period after exercise. I tested the hypothesis that I235N-Kv7.1 primarily causes latent LQT1 by generating relatively normally functioning Kv7.1 channels that are resistant to PKA stimulation.

5.2 Results

5.2.1 Patients genotype positive for I235N-Kv7.1 have latent LQT1

A reliable way to identify patients with LQT1 is to perform ECG exercise treadmill stress testing.\(^53\) A probable diagnosis of latent LQT1 can be determined by calculating the difference between the baseline or resting QTc interval and the QTc interval measured at 3 minutes during the recovery phase (\( \Delta QTc \)). If the \( \Delta QTc \) is \( \geq 30 \text{ ms} \), a pregenetic probability for identifying a mutation in \( KCNQ1 \) is 75\%.\(^53\) Ten members of a large LQT1 family genotype positive for I235N-Kv7.1 whom underwent treadmill stress testing were analyzed (Figure 5.1A). All ten patients had a normal resting QTc interval, but subsequent to the stress test had a \( \Delta QTc > 30 \text{ ms} \) suggesting latent LQT1 (Figure 5.1B). Additionally, QTc interval prolongation persisted at all recovery points following the stress test (Figure
5.1C). Aside from exaggerated QTc interval prolongation during exercise stress testing, the index patient suffered an episode of near drowning (Figure 5.1A, IV:8) and her genotype positive father died suddenly (Figure 5.1A, patient III:5). The clinical data for the family genotype positive for I235N-Kv7.1 is summarized in Table 5.1.

5.2.2 Cells expressing I235N-Kv7.1 largely reduce \( I_{\text{Kv7.1}} \), but coexpression of WT- and I235N-Kv7.1 alleviates the reduction in \( I_{\text{MAX}} \)

Since most LQT1 mutations reduce \( I_{\text{MAX}} \), I voltage-clamped cells expressing KCNE1 and WT-Kv7.1, I235-Kv7.1, or WT- and I235N-Kv7.1 (Figure 5.2A). \( I_{\text{Kv7.1}} \) was recorded by applying the 5-s voltage protocol described previously (Figure 3.2). The peak \( I_{\text{Kv7.1}} \) amplitude recorded during the step pulse (Figure 5.2B) or at the start of the tail pulse (Figure 5.2C) was plotted as a function of the step pulse potential, and the tail \( I_{\text{Kv7.1}} \) was described with a Boltzmann equation for cells expressing WT-Kv7.1 or WT- and I235N-Kv7.1. \( I_{\text{Ks}} \)-like currents were recorded from cells expressing WT-Kv7.1. Cells expressing I235N-Kv7.1 generated small, outward \( I_{\text{Kv7.1}} \) that appeared to activate only at very positive potentials and were too small to accurately fit with a Boltzmann equation. Coexpression of WT- and I235N-Kv7.1 appeared to mostly correct the loss-of-function phenotype: \( I_{\text{MAX}} \) was only reduced by \( \sim 30\% \) (Figure 5.2D), the \( V_{1/2} \) was positively shifted by \( \sim 15 \text{ mV} \) (Figure 5.2E), and the slope factor \( (k) \) was increased by \( \sim 6 \text{ mV/e-fold} \Delta \) (Figure 5.2F). These data suggest that I235N-Kv7.1 causes a severe loss-of-function when expressed alone, but when coexpressed with WT-Kv7.1, it does not.
Indeed, the coexpression of WT- and I235N-Kv7.1 mostly corrected the I235N-Kv7.1 dysfunctional phenotype.

5.2.3 Cells coexpressing WT- and I235N-Kv7.1 prevent PKA stimulation of $I_{K_{V7.1}}$ and phosphomimetic substitution at S27 does not increase $I_{K_{V7.1}}$

Since all patients genotype positive for I235N-Kv7.1 who underwent exercise treadmill stress testing demonstrate latent LQT1, I tested whether I235N-Kv7.1 generates Kv7.1 channels that are insensitive to PKA stimulation. I coexpressed KCNE1 and AKAP9 with WT-Kv7.1 or WT- and I235N-Kv7.1 and recorded $I_{K_{V7.1}}$ using a 5-s voltage protocol similar to Figure 3.2 before and after extracellular perfusion of forskolin and IBMX (Figure 5.3A). Preliminary data showed this cocktail was most effective at raising intracellular cAMP levels and increasing $I_{K_{V7.1}}$ (data not shown). The peak tail $I_{K_{V7.1}}$ was plotted as a function of the step pulse potential for cells expressing WT-Kv7.1 (Figure 5.3B) or WT- and I235N-Kv7.1 (Figure 5.3C), and the data was described with a Boltzmann equation (Figure 5.3D-F). Perfusion of forskolin and IBMX increased the $I_{MAX}$ in cells expressing WT-Kv7.1, but it did not increase $I_{K_{V7.1}}$ recorded from cells coexpressing WT- and I235N-Kv7.1 (Figure 5.3D). These data suggest I235N-Kv7.1 prevents increase of $I_{K_{V7.1}}$ subsequent to PKA stimulation via perfusion of forskolin and IBMX.

There are at least two possibilities as to why I235N-Kv7.1 prevents an increase of $I_{K_{V7.1}}$ after PKA stimulation: (1) I235N-Kv7.1 prevents phosphorylation of S27 from PKA or (2) I235N-Kv7.1 prevents appropriate conformational
changes necessary to increase $I_{Kv7.1}$ after PKA phosphorylation. A recent study suggests phosphomimetic substitution of S27D-Kv7.1 can “rescue” a PKA insensitive LQT1 mutation that disrupts phosphorylation of S27. Therefore, I incorporated a mutation that prevents S27 phosphorylation (S27A-Kv7.1) or a phosphomimetic substitution (S27D-Kv7.1). Using the same 5-s voltage protocol describe previously (Figure 3.2), I recorded $I_{Kv7.1}$ from cells expressing KCNE1 and AKAP9 with either S27A-Kv7.1 or S27D-Kv7.1, and from cells coexpressing S27A- and S27A/I235N-Kv7.1 or S27D- and S27D/I235N-Kv7.1 (Figure 5.4A). The mean peak tail $I_{Kv7.1}$ was plotted as a function of the step pulse potential for cells expressing S27A-Kv7.1 and S27D-Kv7.1 (Figure 5.4B) or cells coexpressing S27A- and S27A/I235N-Kv7.1 and S27D- and S27D/I235N-Kv7.1 (Figure 5.4C), and a Boltzmann equation was used to describe the data as previously described (Figure 3.2). Compared to cells expressing S27A-Kv7.1, $I_{MAX}$ recorded from cells expressing S27D-Kv7.1 was larger (Figure 5.4D). Cells coexpressing S27D- and S27D/I235N-Kv7.1 did not increase $I_{MAX}$ compared to S27A- and S27A/I235N-Kv7.1 cells (Figure 5.4D). Since the phosphomimetic substitution did not increase $I_{Kv7.1}$, these data suggest that I235N-Kv7.1 likely prevents the downstream conformational changes in Kv7.1 channels that are required to increase $I_{Kv7.1}$ after S27 phosphorylation.

5.2.4 Computational simulations suggest $I_{Ks}$ insensitivity to PKA likely contributes to ventricular AP prolongation during β-adrenergic stimulation

To predict how I235N-Kv7.1 might affect the ventricular AP duration over a
wide range of cycle-lengths, we performed simulations using a computational model of a ventricular AP without or with β-adrenergic stimulation (Figure 5.5A, 5.5B, respectively). To mimic the effects that I235N-Kv7.1 might have on I\textsubscript{Ks}, we decreased the I\textsubscript{Ks} amplitude by 30% and made it insensitive to PKA stimulation. We compared these simulations with control I\textsubscript{Ks} or simulations that simply reduced the I\textsubscript{Ks} component by 30% without altering PKA sensitivity. We measured the APD90 at cycle lengths ranging between 0.3 to 1 s to cover a range of heart rates from 200 to 60 bpm, respectively. In the absence of to β-adrenergic stimulation, a 30% reduction in I\textsubscript{Ks} and a 30% reduction in PKA-insensitive I\textsubscript{Ks} resulted in only a 1-2% prolongation of the APD90 over the range of cycle lengths (Figure 5.5A). Including β-adrenergic in the simulations caused a similar increase in the APD90 when the I\textsubscript{Ks} component was reduced by 30%, but reducing the I\textsubscript{Ks} component by 30% and making it insensitive to PKA caused the APD90 to increase by 6% to 10% over cycle lengths ranging from 0.3 to 1 s (Figure 5.5B). These computational simulations suggest that the PKA insensitivity of I\textsubscript{Ks} is a critical determinant of ventricular AP duration, especially with slower heart rates during β-adrenergic activation.

5.3 Discussion

In this chapter, we identified patients genotype positive for I235N-Kv7.1, whereby ten out of ten patients had a normal QTc interval at rest, but abnormal QTc interval prolongation was unmasked following ECG exercise treadmill stress testing. This suggested that I235N-Kv7.1 might cause latent LQT1. Therefore, I
directly evaluated the functional properties of I235N-Kv7.1 with or without PKA stimulation.

Cells coexpressing WT- and I235N-Kv7.1 showed a relatively mild dysfunctional phenotype in basal conditions, but did not increase $I_{\text{MAX}}$ in response to PKA stimulation. These results suggested I235N-Kv7.1 generates PKA-insensitive channels (Figures 5.3). Studies show that β-adrenergic stimulation increases $I_{\text{Kv7.1}}$ by PKA phosphorylation at S27, and phosphomimetic substitution can to mimic the functional increase in $I_{\text{Kv7.1}}$.$^{83,137}$ A recent study shows an LQT1 mutation (A341V-Kv7.1) generates PKA-insensitive $I_{\text{Kv7.1}}$ by decreasing S27 phosphorylation and phosphomimetic substitution at S27 increases the function of A341V-Kv7.1.$^{91}$ Contrary to this study, I determined that phosphomimetic substitution in I235N-Kv7.1 did not increase the mutant channel function (Figure 5.4). Therefore, the PKA-insensitivity of I235N-Kv7.1 is likely secondary to a restriction in the conformational changes necessary to increase $I_{\text{Kv7.1}}$ after S27 is phosphorylated. Incorporating the functional effects of I235N-Kv7.1 on the $I_{\text{Ks}}$ component of a ventricular AP computational simulation showed AP prolongation primarily occurred during β-adrenergic stimulation, and this was exaggerated at slower cycle lengths (Figure 5.5). Together, these data are the first to identify a molecular mechanism for latent LQT1; whereas, $\text{KCNO1}$ mutations that cause a mild reduction in $I_{\text{MAX}}$ in basal conditions and $I_{\text{MAX}}$ does not increase after PKA activation heighten the risk for latent LQT1.
Figure 5.1 Patients genotype positive for I235N-Kv7.1 demonstrate exaggerated QTc prolongation following exercise treadmill stress testing.

A. Shown is a pedigree of a LQT1 family with I235N-Kv7.1 whom underwent
ECG treadmill stress testing. Individual males or females are represented as squares or circles, respectively; each generation is denoted by a Roman numeral; OC denotes an obligate carrier; and the asterisks signify individuals that underwent ECG treadmill stress testing. **B.** The QTc intervals recorded at baseline and after 3 minutes recovery used to calculate the ΔQTc of the ten patients positive for I235N-Kv7.1 whom underwent ECG treadmill stress testing are plotted. **C.** The mean QTc intervals recorded during the stress test were plotted at baseline, peak exercise, and 1, 2, 3, 4, or 5 minutes during recovery. (*) p < 0.05 vs. baseline)
Figure 5.2 The loss-of-function caused by I235N-Kv7.1 is mostly corrected by coexpression of WT-Kv7.1. A. Representative families of whole-cell $I_{\text{Kv7.1}}$ measured from cells expressing KCNE1 and WT-Kv7.1 (WT, black squares, n = 11), I235N-Kv7.1 (I235N, red circles, n = 8), or WT- and I235N-Kv7.1 (WT & I235N, red triangles, n = 12). $I_{\text{Kv7.1}}$ was recorded by applying the 5-s voltage protocol previously described. Mean peak step (B) and tail (C) $I_{\text{Kv7.1}}$ are plotted as a function of the step pulse potential for cells expressing WT-Kv7.1, I235N-
Kv7.1, or WT- and I235N-Kv7.1. Peak tail $I_{Kv7.1}$ were measured at the initiation of the tail pulse and the tail I-V relations were described using a Boltzmann equation for cells expressing WT-Kv7.1 or WT- and I235N-Kv7.1 (gray line, Figure 5.2C). The Boltzmann equation calculated the mean $I_{MAX}$ (D), $V_{1/2}$ (E), and slope factor, $k$ (F). (* $p < 0.05$ vs. cells expressing WT-Kv7.1)
Figure 5.3 $I_{Kv7.1}$ recorded from cells coexpressing WT- and I235N-Kv7.1 is insensitive to PKA stimulation. A. Representative traces of $I_{Kv7.1}$ measured from cells expressing KCNE1 and AKAP9 with WT-Kv7.1 (WT, n = 6) or WT- and...
I235N-Kv7.1 (WT & I235N, n = 6) before and after extracellular perfusion of 10 μM forskolin and 0.2 mM IBMX are shown. \( I_{Kv7.1} \) was recorded by applying step pulse from -80 to 80 mV in 20-mV increments for 5 s, followed by a tail pulse to -50 mV for 5 s. The voltage protocol is display in the inset. The mean peak tail \( I_{Kv7.1} \) are plotted as a function of the step pulse potential for cells expressing (B) WT-Kv7.1 before (black squares) and after (black open squares) perfusion or (C) WT- and I235N-Kv7.1 before (red triangles) and after (red open triangles) perfusion. The peak tail I-V relations for cells expressing WT-Kv7.1 or WT- and I235N-Kv7.1 were described using a Boltzmann equation (gray line, Figure 5.3B-C) to calculate the \( I_{\text{MAX}} \) (D), \( V_{1/2} \) (E), and \( k \) (F). (* p < 0.05 vs. before perfusion)
Figure 5.4 Phosphomimetic substitution of S27D does not increase $I_{\text{Kv7.1}}$ for I235N-Kv7.1. A. Representative traces of whole-cell $I_{\text{Kv7.1}}$ measured from cells expressing KCNE1 and AKAP9 with S27A-Kv7.1 (S27A, black squares, n = 5),
S27D-Kv7.1 (S27D, black open squares, n = 5), S27A- and S27A/I235N-Kv7.1 (S27A & S27A/I235N, red triangles, n = 7), or S27D- and S27D/I235N-Kv7.1 (S27D & S27D/I235N, red open triangles, n = 9) are displayed. \(I_{Kv7.1}\) was recorded by applying the 5-s voltage protocol previously described. The mean peak tail \(I_{Kv7.1}\) are plotted as a function of the step pulse potential for cells expressing (B) S27A-Kv7.1 or S27D-Kv7.1 and (C) S27A- and S27A/I235N-Kv7.1 or S27D- and S27D/I235N-Kv7.1. The peak tail \(I-V\) relations were described using a Boltzmann equation (gray line, Figure 5.3B-C) to calculate the \(I_{MAX}(D), V_\frac{1}{2}(E)\), and \(k(F)\). (* \(p < 0.05\) vs. S27A)
Figure 5.5 Computational simulations of ventricular AP with or without β-adrenergic stimulation. Computational simulations of a rabbit ventricular for control $I_{Ks}$ (black squares), $I_{Ks}$ reduced by 30% (blue circles), or $I_{Ks}$ reduced by 30% and insensitive to PKA stimulation (red triangles). The APD90 is plotted as a function of cycle length in basal conditions (A) or with simulating β-adrenergic stimulation (B). C. The corresponding ventricular AP waveform and $I_{Ks}$ density is displayed. Black traces represent control $I_{Ks}$, blue traces represent simulations in
which the $I_{Ks}$ component was reduced by 30%, and red traces represent simulations in which the $I_{Ks}$ component was reduced by 30% and was also insensitive to PKA stimulation. (These data were obtained in collaboration with Dr. Don E. Burgess)
Table 5.1 Clinical characteristics of patients genotype positive for I235N-Kv7.1

<table>
<thead>
<tr>
<th>I235N-Kv7.1 patient data</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype positive subjects, n (female, n)</td>
<td>15 (6)</td>
</tr>
<tr>
<td>ECG treadmill stress test, n (female, n)</td>
<td>10 (3)</td>
</tr>
<tr>
<td>Mean age ± SD (years)</td>
<td>38 ± 14</td>
</tr>
<tr>
<td>Female mean age ± SD (years)</td>
<td>46 ± 19</td>
</tr>
<tr>
<td>Male mean age ± SD (years)</td>
<td>35 ± 11</td>
</tr>
<tr>
<td>Mean resting QTc ± SD (ms)</td>
<td>445 ± 16</td>
</tr>
<tr>
<td>Female mean resting QTc ± SD (ms)</td>
<td>441 ± 24</td>
</tr>
<tr>
<td>Male mean resting QTc ± SD (ms)</td>
<td>446 ± 14</td>
</tr>
<tr>
<td>Mean ΔQTc ± SD (ms)</td>
<td>76 ± 29</td>
</tr>
<tr>
<td>Female mean ΔQTc ± SD (ms)</td>
<td>88 ± 40</td>
</tr>
<tr>
<td>Male mean ΔQTc ± SD (ms)</td>
<td>71 ± 25</td>
</tr>
<tr>
<td>Near drowning episode, n (female, n)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Sudden cardiac death, n (female, n)</td>
<td>1 (0)</td>
</tr>
</tbody>
</table>
Chapter 6
General Discussion

6.1 Overall significance

Over the past 15 years, KCNQ1 mutations that alter normal Kv7.1 function have been linked to congenital arrhythmia syndromes. Most commonly, loss-of-function KCNQ1 mutations associate with LQT1 and are functionally defined as haploinsufficient, dominant-negative, or dominant-negative and PKA-insensitive.\(^1\)\(^2\),\(^3\)\(^4\)\(^5\)\(^6\)\(^7\)\(^8\)\(^9\)\(^10\)\(^11\)\(^12\)\(^13\) Defining these mutations as loss-of-function is a helpful way to link a functional phenotype with a clinical phenotype, but LQT1 has incomplete penetrance and it does not satisfactorily explain patients with pleiotropic or latent phenotypes.\(^1\)\(^2\)\(^3\)\(^4\)\(^5\) My findings indicate that the functional phenotypes are more complex and the loss-of-function definition is an oversimplification. I suspect that refining the categorization of LQT1 classification to include multiple functional phenotypes could improve patient management.

I have identified two distinct LQT1-associated functional phenotypes: 1) a pleiotropic phenotype capable of causing multiple arrhythmia syndromes, and 2) a phenotype that causes a relatively benign functional phenotype, but primarily is insensitive to PKA stimulation. My data show that the maximally activated tail \(I_{Kv7.1} (I_{\text{MAX}})\) and PKA sensitivity of mutant Kv7.1 channels (when coexpressed with WT-Kv7.1) correlates to mutation-specific differences in LQT1 patient phenotypes. Although a gap remains between a genotype positive result and complete penetrance, these findings progress our understanding of Kv7.1’s role
(and its gene, **KCNQ1**) in cardiac repolarization and monogenic arrhythmia syndromes.

6.2 **KCNQ1 mutations associated with a mixed clinical phenotype of long QT syndrome and atrial fibrillation**

With the important finding that there is a 20-fold higher prevalence of AF in patients with LQTS compared to the general population comes the question: How is this possible?\(^{70}\) Consistent with these observations and my own, studies show the degree of QTc interval prolongation varies among patients genotype positive for AF-linked gain-of-function **KCNQ1** mutations.\(^{63-65, 111, 126, 133}\)

Interestingly, QTc interval prolongation has long been observed in patients diagnosed with AF, but a debate over this issue has ensued because determining the QTc interval in a patient with AF is difficult.\(^{144}\) On an ECG, the QT interval is directly influenced by the duration of the preceding heart beat (ventricular AP duration) and the heart rate.\(^{145, 146}\) This means that a change in AP duration causes an immediate adjustment in the QT interval and the subsequent QT intervals will also be affected by a new prevailing heart rate.\(^{144}\)

Therefore, determining the QTc interval in a patient who has AF is difficult to assess because of the irregularities in time between each successive beat and the variations in their heart rate.

The coexistence of LQT1 and AF is surprising because of the distinct classification of LQT1- or AF-linked **KCNQ1** mutations as a loss- or gain-of-function, respectively. My work has revealed functional phenotypes to distinguish
why some LQT1-linked \textit{KCNQ1} mutations associate with a higher-risk for development of AF. In chapters 3 and 4, I analyzed two mutations of the same conserved arginine residue in the Kv7.1 S4 transmembrane segment, R231C-Kv7.1 and R231H-Kv7.1, and other gain-of-function AF-linked \textit{KCNQ1} mutations (S140G-Kv7.1 and V141M-Kv7.1). I found R231H-Kv7.1 is the only mutation that does not reduce \(I_{\text{MAX}}\) when coexpressed with WT-Kv7.1 (Figure 4.8C). This is somewhat contradictory to what has previously been published for S140G-Kv7.1 and V141M-Kv7.1.\textsuperscript{63, 64} Studies suggest that both of these mutations cause a gain-of-function when coexpressed with WT-Kv7.1. However, these studies use voltage protocols that utilized shorter depolarizing step pulses. I re-plotted the peak step \(I_{\text{Kv7.1}}\) as a function of the step pulse potential at the 1-s (Figure 6.1A) and 2-s (Figure 6.1B) time points for cells expressing KCNE1 with WT-Kv7.1, WT- and S140G-Kv7.1, WT- and V141M-Kv7.1, WT- and R231C-Kv7.1, or WT- and R231H-Kv7.1. At 1-s, cells coexpressing WT-Kv7.1 and mutant Kv7.1 all increased \(I_{\text{Kv7.1}}\) at positive potentials (Figure 6.1C). At 2-s, cells coexpressing WT-Kv7.1 and mutant Kv7.1 were larger at most potentials (Figure 6.1D). However, at the 5-s time point, cells coexpressing WT-Kv7.1 and mutant Kv7.1 did not conduct larger \(I_{\text{Kv7.1}}\) when compared to cells expressing WT-Kv7.1. In fact, a reduction in \(I_{\text{Kv7.1}}\) was observed from cells coexpressing WT- and V141M-Kv7.1 or R231C-Kv7.1 at potentials of 50-70 mV (Figure 6.1E). This highlights the problem associated with a gain-of-function versus loss-of-function categorization, because it depends on the voltage protocol or expression systems used to measure \(I_{\text{Kv7.1}}\).
My data suggest measuring the peak tail $I_{Kv7.1}$ after approaching a steady-state of maximal activation is reliable in equating functional and clinical phenotypes. If we review the clinical data for families genotype positive for S140G-Kv7.1, V141M-Kv7.1, R231C-Kv7.1, or R231H-Kv7.1 (Table 6.1), we can see that all are linked to AF and all increase constitutive activation of $I_{Kv7.1}$. My data suggest constitutive $I_{Kv7.1}$ at negative potentials is an important determinant for AF susceptibility and likely contributes to atrial AP shortening and reduced atrial refractoriness. For families genotype positive of either S140G-Kv7.1 or R231C-Kv7.1, the observation of a prolonged QTc interval in 56 or 44% of patients, respectively, is also observed. Consistent with this, coexpressing WT-Kv7.1 and S140G-Kv7.1 or R231C-Kv7.1 reduced tail $I_{MAX}$ when compared to cells expressing WT-Kv7.1. Importantly, the majority of patients genotype positive for R231H-Kv7.1 (86%) have normal QTc intervals and coexpression of WT- and R231H-Kv7.1 does not reduce tail $I_{MAX}$. Furthermore, R231H-Kv7.1 was the only mutation that is linked to familial cases of early-onset AF in multiple unrelated families suggesting that R231H-Kv7.1 causes a higher-risk functional phenotype for AF susceptibility.

6.3 Recent discoveries of patients genotype positive for R231C-Kv7.1 and importance for understanding pleiotropic mutations

R231C-Kv7.1 was originally reported in patients with severe LQT1, and we later identified five additional families with R231C-Kv7.1 that have a family-specific risk to either LQT1 or AF. Since my previous report, more families
genotype positive for R231C-Kv7.1 with LQT1 and/or AF have been identified.\textsuperscript{147} R231C-Kv7.1 was identified in a girl and was diagnosed with LQT1 and early-onset AF, and two other family members genotype positive for R231C-Kv7.1 have a history of LQTS.\textsuperscript{147} The second report identified two families genotype positive for R231C-Kv7.1 with a history of LQT1 and/or AF.\textsuperscript{148} The first family revealed two female R231C-Kv7.1 patients with LQT1, whereby in the latter family, six patients were genotype positive for R231C-Kv7.1. The mother has LQT1 and early-onset AF, one patient has early-onset AF, and three additional patients had a history of LQT1 or sudden cardiac death.\textsuperscript{148}

It is clear that patients with the R231C-Kv7.1 mutation present with variable clinical phenotypes of LQT1 and/or AF. These new discoveries support my findings that a distinct functional phenotype predisposes R231C-Kv7.1 patients to both LQT1 and AF; whereas, the constitutive $I_{Kv7.1}$ predisposes patients to AF and the decrease in tail $I_{MAX}$ increases the risk of LQT1.\textsuperscript{111}

Including R231C-Kv7.1, we have discussed three $KCNQ1$ mutations linked to QTc interval prolongation and AF thus far, and most likely, as genetic testing continues more mutations will be associated with both arrhythmia syndromes.\textsuperscript{63, 126} A problem arises for pharmacological treatments of these patients because drug therapy for AF is contraindicated in patients with a prolonged QTc interval.\textsuperscript{149-151} Several drugs used for AF actually can induce QTc interval prolongation and further increase the risk of torsades de pointes in LQT1 patients.\textsuperscript{34} Therefore, unique pleiotropic mutations capable of causing multiple arrhythmia syndromes like these should be thoroughly evaluated in the future to
direct the appropriate intervention in patients with multiple arrhythmia syndromes associated to different functional phenotypes.

Although R231C-Kv7.1 is the first KCNQ1 mutation described to be capable of pleiotropic expression, this observation is also linked to individual mutations in genes encoding several other ion channels. Particularly, mutations in SNC5A (which encodes Nav1.5) associate with overlapping clinical phenotypes such as LQT3 or Brugada syndrome. These mutations generate a mixed functional phenotype causing impairments in inactivation that increase late $I_{Na}$ similar to LQT3-linked SCN5A mutations, but also reduce overall Nav channel availability comparably to Brugada-linked mutations. A study suggests that even mutations in adapter protein genes, such as ANK2, can be causative of multiple arrhythmia syndromes (LQT4, bradycardia, and AF) in a single family by disrupting localization of Na⁺/K⁺-ATPase and/or Na⁺/Ca²⁺ exchanger. In combination with my work, these studies emphasize that the complex nature of channelopathies can be unpredictable. Relating the pleiotropic functional phenotypes of mutations associated to multiple arrhythmia syndromes can improve the therapeutic management in these patients.

6.4 Exercise treadmill stress testing correlates clinical observations with a molecular mechanism

Recent studies analyzing data from the International LQTS registry and functional studies suggest PKA-insensitive LQT1 mutations increase the risk for life-threatening events compared to other transmembrane LQT1 mutations that
respond to PKA stimulation. These studies also imply patients with PKA-insensitive LQT1 mutations might benefit more with β-blocker therapy. Regardless, patients identified with clinically proven LQT1 mutations that fail to manifest any obvious clinical symptoms (latent LQT1) are hard to treat, and molecular mechanisms that underlie a latent LQT1 phenotype have yet to be determined. Furthermore, studies show that genotype positive individuals with concealed LQTS still have a > 10-fold relative risk of sudden cardiac death than genotype-negative family members. A reliable comprehensive approach is needed to accurately predict mutation-specific risks associated with patients that are genotype positive for LQT1-linked mutations to better treat patients with elevated susceptibility to arrhythmogenic events. We propose a method (ECG treadmill stress testing) to reveal latent LQT1 phenotypes in families with concealed LQT1 and assess a mutation-specific risk for this elusive subtype of LQT1.

A non-invasive clinical tool to assess the QTc interval response to β-adrenergic activation is the ECG exercise treadmill stress test. Specifically, measuring QTc intervals during the recovery phase following treadmill testing is a reliable method for pre-genetically distinguishing LQT1 patients from control or other LQTS types. Using this clinical tool, we identified a large, multigenerational family genotype positive for I235N-Kv7.1 and all ten patients whom underwent treadmill stress testing met the criteria for latent LQT1. Functional analyses showed I235N-Kv7.1 caused a severe loss-of-function phenotype, but coexpression of WT- and I235N-Kv7.1 mostly restored normal
function (Figure 5.2). These data suggest that I235N-Kv7.1 does not cause dominant negative suppression of $I_{Kv7.1}$ and contradict functional studies performed in *Xenopus laevis* oocytes.\textsuperscript{158} We suspect discrepancies between our studies might be due to the expression system used, and previous studies have highlighted problems with interpreting functional properties of LQTS mutations in *Xenopus laevis* oocytes.\textsuperscript{159,160}

More importantly, further functional analyses suggested that cells coexpressing WT- and I235N-Kv7.1 conducted $I_{Kv7.1}$ that were insensitive to PKA stimulation following perfusion of forskolin and IBMX (Figure 5.3). A recent study shows that a dominant-negative PKA-insensitive LQT1 mutation (A341V-Kv7.1) reduces Kv7.1 phosphorylation following PKA stimulation, and prevents a functional increase in $I_{Kv7.1}$.\textsuperscript{91} The functional increase of $I_{Kv7.1}$ from cells expressing A341V-Kv7.1 is rescued by phosphomimetic substitution, which further supports the initial concept that this mutation prevented Kv7.1 from being phosphorylated.\textsuperscript{91} My data suggest that the relatively benign I235N-Kv7.1 disrupts PKA-sensitivity by restricting conformational changes necessary to increase $I_{Kv7.1}$ following PKA stimulation because phosphomimetic substitution did not increase $I_{Kv7.1}$ (Figure 5.4). These results might explain why patients genotype positive for I235N-Kv7.1 have a normal QTc interval at rest, but, exaggerated QTc interval prolongation persists following β-adrenergic stimulation (exercise treadmill stress testing).

In addition to exercise treadmill stress testing, measuring patient-specific differences in autonomic reflexes may also be used to identify high-risk LQT1
patients. LQT1 patients who are at a higher risk for experiencing symptoms have a faster decline in heart rate within the first minute after cessation of a bicycle ergometer exercise stress test. Similar, our use of exercise treadmill stress testing also focuses on time points during the recovery phase, where exaggerated QTc interval prolongation is noted. Both stress tests imply the importance of I\textsubscript{Ks} in regulating ventricular AP duration within seconds to minutes following the conclusion of exercise testing. During recovery, powerful vagal reflexes work to slow the heart rate, but sympathoadrenal signaling (circulating levels of epinephrine and norepinephrine) remains elevated. This means that as the heart rate slows, β-adrenergic receptors are still activated. Remarkably, our computational simulations of a ventricular AP shows that including the functional effects of I\textsubscript{235N-Kv7.1} in the I\textsubscript{Ks} component primarily cause AP prolongation with β-adrenergic stimulation, and AP prolongation is exaggerated at slower cycle lengths (Figure 5.5). These data suggest that exercise stress testing might be useful for identifying patients with KCNQ1 mutations that generate PKA-insensitive Kv7.1 channels, and patients with latent LQT1 may benefit more from β-blocker therapy than other symptomatic patients.

PKA-insensitive mutant Kv7.1 channels are being increasingly linked as a risk factor of symptoms, and a noninvasive technique to assess these issues is needed. The first LQT1 mutation shown to decrease PKA-sensitivity of I\textsubscript{Kv7.1} was a mutation within the leucine zipper motif of Kv7.1, G589D-Kv7.1, and this mutation disrupted AKAP9 from binding to C-terminus of Kv7.1. Additionally, a missense mutation in the gene encoding AKAP9 is associated with LQT11 and
similarly causes a reduction in the interaction between Kv7.1 and AKAP9.\textsuperscript{90} As mentioned, a mutation in the Kv7.1 S6 transmembrane segment, A341V-Kv7.1, was shown to generate PKA-insensitive Kv7.1 channels by preventing PKA phosphorylation at S27.\textsuperscript{91} Most recently, several LQT1 mutations located in the cytoplasmic loops linking S2-S3 or S4-S5 transmembrane segments were shown to be resistant to PKA stimulation by forskolin.\textsuperscript{92} Although in chapter 4, I suggested that R231H-Kv7.1 does not cause a loss-of-function phenotype similar to LQT1 mutations and has a high propensity to cause AF, several patients had borderline QTc intervals or epinephrine induced QTc prolongation suggesting ventricular abnormalities.\textsuperscript{128} Utilizing a similar approach, I tested whether R231H-Kv7.1 prevented PKA-induced increase of $I_{Kv7.1}$ from cells coexpressing R231H-Kv7.1 (KCNE1 and AKAP9 were also coexpressed). As expected, PKA stimulation increased the mean peak tail $I_{Kv7.1}$ in cells expressing WT-Kv7.1 by almost 2-fold (Figure 6.2B), but Cells expressing R231H-Kv7.1 did not (Figure 6.2B). These data suggest that R231H-Kv7.1 might also suppress PKA stimulation of $I_{Kv7.1}$. I have now shown two mutations, both located in the Kv7.1 S4 transmembrane segments (R231H-Kv7.1 and I235N-Kv7.1) to be insensitive to PKA stimulation, which is evidence to predict that more $KCNQ1$ mutations located in the transmembrane regions of Kv7.1 will be PKA-insensitive.\textsuperscript{126}

Together, these data propose that exercise treadmill stress testing (and possibly epinephrine testing) might aid in revealing mutations that cause PKA-insensitive Kv7.1 channels in patients with latent LQT1. To the best of my knowledge these are the first data to link PKA-insensitivity to an abnormal ECG
exercise stress test. Whether or not KCNQ1 mutations commonly generate PKA-insensitive Kv7.1 channels warrants further investigation. These findings represent a significant breakthrough in correlating the predictive value of a non-invasive clinical technique with molecular mechanisms/functional phenotypes of LQT1 mutations. Future testing incorporating exercise treadmill stress testing in combination with mutation-specific risk assessment can improve individual LQT1 patient treatment.

6.5 Kv7.1 voltage sensor mutations

In this dissertation, I studied the functional properties of three mutations located within the Kv7.1 voltage-sensing S4 transmembrane segment (R231C-Kv7.1, R231H-Kv7.1, and I235N-Kv7.1) that are associated with three different clinical characteristics. Cells expressing these mutant Kv7.1 channels with KCNE1 all alter voltage dependence of activation when compared to WT-Kv7.1 expressing cells, but do so by generating three distinct functional phenotypes: 1) large constitutive $I_{\text{Kv7.1}}$, 2) constitutive $I_{\text{Kv7.1}}$ of similar tail $I_{\text{MAX}}$, and 3) positive shift in voltage dependence of activation. This is interesting because two of these mutations alter the same residue (R231) and the third mutation is only four amino acid residues downstream (I235).

Several studies show LQT1 mutations located in the Kv7.1 S4 transmembrane segment reduce $I_{\text{Kv7.1}}$, slow the time course of activation, or cause a positive shift in the voltage dependence of activation, similar to I235N-Kv7.1.\(^{110, 158, 165, 166}\) Aside from the voltage sensor, a report shows three LQT1-
linked Kv7.1 mutations located in a region critical for cell surface expression and within close proximity to one another cause variable dysfunction and surface expression of Kv7.1. In the neuronally expressed Kv7.2 channel, two mutations of the same conserved arginine residue in S4 associate with benign or severe forms of neonatal-onset encephalopathies. Both of these mutations cause a positive shift in the voltage dependence of activation and increase the time course of deactivation of Kv7.2 to variable degrees, suggesting a variable predisposition to severity of disease, similar to R231C-Kv7.1 and R231H-Kv7.1. Furthermore, our lab shows that mutations linked to LQT2 in the Kv11.1 S4 conserved arginine residues that are only three residues apart also cause variable gating abnormalities or cell surface expression of Kv11.1.

Mutations of specific charged amino acid residues of the S4 transmembrane segment are not isolated to Kv channels. S4 mutations of Nav1.1 are linked to congenital cases of epilepsy and cause a gain-of-function phenotype by destabilizing inactivation and increasing persistent $I_{Na}$ similar to LQT3-related Nav1.5 mutations. In Nav1.4 channels, similar S4 gain-of-function mutations are associated with paramyotonia by destabilizing inactivation and slowing the time course of deactivation. Also, Cav2.1 gain-of-function S4 mutations increase the open probability and channel density to cause an increased risk of hemiplegic migraines.

Together, these studies suggest that S4 voltage-sensing mutations continue to be a hot spot for disrupting gating properties of voltage-gated ion channels. Furthermore, they show the proximity of an amino acid residue to a known
mutation is not sufficient to predict functional phenotypes. The association of mutations within the S4 voltage-sensing domain with severe clinical phenotypes highlights the consequence that disrupting important charges critical for sensing changes in membrane potentials has in proper gating and channel function.

6.6 Concluding statement

The simple binary definition of a gain-of-function versus loss-of-function mutation is problematic in determining the risk for disease because a mutation-specific overlap in clinical phenotypes exists.\textsuperscript{63, 71, 111, 126} I was able to identify a pleiotropic functional phenotype that can explain the overlap in clinical phenotypes observed in patients with R231C-Kv7.1 (and possibly S140G-Kv7.1). Also, I identified a higher-risk functional phenotype for association with a high prevalence of AF for patients genotype positive for R231H-Kv7.1. This suggests that analysis of the peak tail $I_{\text{MAX}}$ is indicative of whether or not QTc interval prolongation will be observed in patients. Also, these data support that the presence of constitutive $I_{\text{Kv7.1}}$ is increases the risk of reduced atrial refractoriness and subsequently AF. Furthermore, in patients with latent LQT1, we directly linked a molecular mechanism with a clinical stress test evaluation. I235N-Kv7.1 generates a benign functional phenotype that is resistant to PKA stimulation and increases the risk for exaggerated QTc interval prolongation or latent LQT1 phenotypes during exercise. The findings and implications of this dissertation help determine the role of Kv7.1 in atrial and ventricular AP repolarization by directly linking clinical observations with functional data.
6.7 Future Studies

Concrete evidence explaining disparity of patient-specific differences that influence the prevalence of disease is not yet determined. Results from this dissertation using a heterologous expression system can explain possible molecular mechanisms of arrhythmia for genotype-positive patients, but it still does not clarify why penetrance of these congenital arrhythmia syndromes are not 100%. Using heterologous expression systems are very useful in studying biophysical properties of LQT1 mutations, however the lack of important auxiliary subunits or regulatory proteins does not recapitulate the exact macromolecular environment in a human heart. Most often, mouse models are used to study congenital cardiovascular diseases, but using transgenic LQT1 mouse models is problematic because $I_{Ks}$ does not contribute to cardiac repolarization. Recent developments in techniques to turn human patients’ fibroblasts into inducible pluripotent stem cells and then, further differentiate these cells into cardiac-like myocytes has excited the fields of congenital disease.

In LQT1, studying the electrical properties of patient-derived cardiac-like myocytes might aid in understanding patient-specific differences that affect variable penetrance of disease within families carrying the same mutation. Several groups have shown that this technique can be useful when studying different types of LQTS, including LQT1; whereas, cardiac-like myocytes derived from symptomatic genotype-positive patients show anticipated AP prolongation,
inducible EADs, and drug sensitive currents.\textsuperscript{177-180} Studying mutations associated with multiple clinical phenotypes such as, R231C-Kv7.1 or R231H-Kv7.1, might be beneficial in our understanding of patient-specific risk factors. With consent, obtaining samples of symptomatic or asymptomatic mutation carriers as well as genotype-negative patients from the families studied or control patients from the general population would be an interesting approach to study the electrical differences in cardiac-like myocytes. Studying R231C-Kv7.1 or R231H-Kv7.1 provides an additional value because not only are there differences within a single family, rather both mutations are found in multiple unrelated families that associate to family-specific clinical phenotypes as well. Cells derived from patients genotype positive for I235N-Kv7.1 or other mutations causative of the latent LQT1 phenotype might also help understand the role of β-adrenergic regulation of Kv7.1 and LQT1-related events.

Although encouraging, the technique of using patient-specific inducible pluripotent stem cells does have limitations. Upon differentiation, the cardiac-like myocytes generated are a milieu of cells with electrophysiological features of nodal, atrial, or ventricular myocytes and selectable markers to distinguish cell types are needed.\textsuperscript{181} Also, cardiac-like myocytes have immature electrophysiological features that resemble fetal cardiomyocytes, and do not express the same proportion of several ion channels or the regulatory proteins in macromolecular complexes expressed in the adult human heart.\textsuperscript{177-184} Lastly, it is impossible to account for environmental influence on gene expression, and this system obviously cannot recapitulate the events of one individual’s unique
development that may alter susceptibility to clinical phenotypes. Nonetheless, until we can account for all limitations, the use of patient derived cardiac-like myocytes provides a positive initiative to understand patient-specific differences in congenital arrhythmia syndromes.
Figure 6.1 Analysis of step pulse for AF mutants at 1, 2, and 5 seconds.

Mean peak step $i_{Kv7.1}$ are plotted as a function of the step pulse potential at 1-s (A) or 2-s (B) for cells expressing WT-Kv7.1 (black squares), WT- and S140G-Kv7.1 (wine open circles), WT- and V141M-Kv7.1 (green diamonds), WT- and
R231C-Kv7.1 (red triangles), or WT- and R231H-Kv7.1 (blue open triangles). The mean peak step $I_{Kv7.1}$ is shown for the 40, 50, 60, and 70 mV step pulse at 1-s (A), 2-s (B), or 5-s (C) time points. (* $p < 0.05$ vs. cells expressing WT-Kv7.1)
Figure 6.2 R231H-Kv7.1 is insensitive to PKA stimulation. A. Representative $I_{Kv7.1}$ traces of cells coexpressing WT-Kv7.1 (WT & AKAP9, $n = 5$) or R231H-Kv7.1 (R231H & AKAP9, $n = 5$) with KCNE1 and AKAP9 were recorded before and after extracellular perfusion of Forskolin and IBMX. $I_{Kv7.1}$ was recorded from a holding potential of -80 mV by applying a depolarizing step pulse to 50 mV for 5
s followed by a tail pulse to -50 mV for 5 s before and after extracellular perfusion of forskolin and IBMX (see inset). B. The bar graph compares the mean peak tail $I_{Kv7.1}$ recorded before and after perfusion. (* $p < 0.05$ vs. before perfusion)
**TABLE 6.1 Clinical characteristics of families genotype positive for KCNQ1 mutations linked to early-onset AF**

<table>
<thead>
<tr>
<th><strong>S140G-Kv7.1 patient data</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype positive S140G families, n</td>
<td>1</td>
</tr>
<tr>
<td>Families with history of LQT1</td>
<td>1</td>
</tr>
<tr>
<td>Families with history of familial AF</td>
<td>1</td>
</tr>
<tr>
<td>Genotype positive subjects, n (female, n)</td>
<td>16 (9)</td>
</tr>
<tr>
<td>Mean QTc ± SD (ms)</td>
<td>453 ± 47</td>
</tr>
<tr>
<td>Female mean QTc ± SD (ms)</td>
<td>451 ± 42</td>
</tr>
<tr>
<td>Male mean QTc ± SD (ms)</td>
<td>456 ± 56</td>
</tr>
<tr>
<td>Prolonged QTc interval, n (female, n)</td>
<td>9 (4)</td>
</tr>
<tr>
<td>Symptomatic, n (female, n)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Early onset AF, n (female, n)</td>
<td>15 (8)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>V141M-Kv7.1 patient data</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype positive V141M families, n</td>
<td>1</td>
</tr>
<tr>
<td>Families with history of LQT1</td>
<td>0</td>
</tr>
<tr>
<td>Families with history of familial AF</td>
<td>1</td>
</tr>
<tr>
<td>Genotype positive patients, n (female, n)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Patient QTc (ms)</td>
<td>280</td>
</tr>
<tr>
<td>Prolonged QTc interval, n (female, n)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Symptomatic, n (female, n)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Early-onset AF, n (female, n)</td>
<td>1 (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>R231C-Kv7.1 patient data</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype positive R231C families, n</td>
<td>6</td>
</tr>
<tr>
<td>Families with history of LQT1</td>
<td>5</td>
</tr>
<tr>
<td>Families with history of familial AF</td>
<td>1</td>
</tr>
<tr>
<td>Genotype positive subjects, n (female, n)</td>
<td>18 (9)</td>
</tr>
<tr>
<td>Mean QTc ± SD (ms)</td>
<td>452 ± 48</td>
</tr>
<tr>
<td>Female mean QTc ± SD (ms)</td>
<td>459 ± 32</td>
</tr>
<tr>
<td>Male mean QTc ± SD (ms)</td>
<td>443 ± 61</td>
</tr>
<tr>
<td>Prolonged QTc interval, n (female, n)</td>
<td>8 (5)</td>
</tr>
<tr>
<td>Symptomatic, n (female, n)</td>
<td>1 (0)</td>
</tr>
<tr>
<td>Early onset AF, n (female, n)</td>
<td>4 (1)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>R231H-Kv7.1 patient data</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype positive R231H families, n</td>
<td>5</td>
</tr>
<tr>
<td>Families with history of LQT1</td>
<td>1</td>
</tr>
<tr>
<td>Families with history of familial AF</td>
<td>4</td>
</tr>
<tr>
<td>Genotype positive patients, n (female, n)</td>
<td>14 (9)</td>
</tr>
<tr>
<td>Mean QTc ± SD (ms)</td>
<td>444 ± 20</td>
</tr>
<tr>
<td>Female mean QTc ± SD (ms)</td>
<td>446 ± 16</td>
</tr>
<tr>
<td>Male mean QTc ± SD (ms)</td>
<td>441 ± 27</td>
</tr>
<tr>
<td>Prolonged QTc interval, n (female, n)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Symptomatic, n (female, n)</td>
<td>3 (3)</td>
</tr>
<tr>
<td>Early-onset AF, n (female, n)</td>
<td>11 (8)</td>
</tr>
</tbody>
</table>
Appendix A.

Limitations

These data were obtained in a widely used heterologous overexpression system (HEK293 cells). The endogenous currents and proteins expressed in the HEK293 cell system could differ from native myocytes. To reduce the interference of endogenous HEK293 cells, the tail pulse was used to distinguish differences between current densities because endogenous currents are not activated at -50 mV. Also, the desired ratio of protein expression are not exact due to the use of transient transfections of multiple DNA plasmids. Therefore, control cells expressing WT-Kv7.1 with the appropriate KCNE β-subunit were always compared to cells expressing mutant Kv7.1 channels on each occasion of data acquisition. The perfusion of forskolin and IBMX could have off-target effects that activate other signaling cascades than intended and could induce alternative channel regulation. Also, the perfusion itself could have altered channel biophysics; therefore, even cells expressing WT-Kv7.1 that did not increase \( I_{\text{Kv7.1}} \) post-perfusion were used in data analysis. The phosphomimetic substitution of S27D-Kv7.1 does not mimic phosphorylation of S27 exactly, and the results of the substitution could be misleading.

Furthermore, families genotype positive for the mutations discussed in this dissertation could still be discovered, and additional families most likely will be found considering the ease and availability of genetic testing today. Therefore, the families discussed could be an “under-assumption” of the true prevalence of LQT1, AF, or concealed LQT1 within the general population. Unidentified patient
specific differences may also contribute to the different clinical phenotypes associated with unrelated families harboring the same mutation.

Lastly, the computational models used are in silico simulations and are used only for didactic purposes. For β-adrenergic simulations, a rabbit ventricular model was used, and electrical properties of a rabbit are not identical to a human. Therefore, the mechanisms of arrhythmias proposed by these models could be inaccurate in predicting outcomes in a native system.
References

5. Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall. *Basic Res Cardiol*. 2001;96:517-527
16. Lopatin AN, Nichols CG. Inward rectifiers in the heart: An update on i(k1). *J Mol Cell Cardiol*. 2001;33:625-638


46. Bazett HC. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. *J Physiol*. 1920;53:320-339
53. Horner JM, Horner MM, Ackerman MJ. The diagnostic utility of recovery phase qtc during treadmill exercise stress testing in the evaluation of long qt syndrome. *Heart Rhythm.* 2011;8:1698-1704


Lundby A, Ravn LS, Svendsen JH, Olesen SP, Schmitt N. Kcnq1 mutation q147r is associated with atrial fibrillation and prolonged qt interval. Heart Rhythm. 2007;4:1532-1541


Walsh KB, Kass RS. Regulation of a heart potassium channel by protein kinase a and c. Science. 1988;242:67-69


Lakatta EG, DiFrancesco D. What keeps us ticking: A funny current, a calcium clock, or both? J Mol Cell Cardiol. 2009;47:157-170

80. Harvey RD, Hell JW. Cav1.2 signaling complexes in the heart. *J Mol Cell Cardiol*. 2013;58:143-152
91. Heijman J, Spatjens RL, Seyen SR, Lentink V, Kuijpers HJ, Boulet IR, de Windt LJ, David M, Volders PG. Dominant-negative control of camp-


syndrome through activation of the nnos-scn5a macromolecular complex. Proc Natl Acad Sci U S A. 2008;105:9355-9360


118. Lengyel C, Jost N, Virag L, Varro A, Lathrop DA, Papp JG. Pharmacological block of the slow component of the outward delayed rectifier current (i(ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. *Br J Pharmacol.* 2001;132:101-110


132. Rocheleau JM, Kobertz WR. Kcne peptides differently affect voltage sensor equilibrium and equilibration rates in kcnq1 k+ channels. *J Gen Physiol.* 2008;131:59-68


potassium channel modify disease severity in patients with type 1 long qt syndrome in an allele-specific manner. *Eur Heart J*. 2012;33:714-723


171. Fan Z, George AL, Jr., Kyle JW, Makielski JC. Two human paramyotonia congenita mutations have opposite effects on lidocaine block of na+ channels expressed in a mammalian cell line. J Physiol. 1996;496 ( Pt 1):275-286


175. Drici MD, Arrighi I, Chouabe C, Mann JR, Lazdunski M, Romey G, Barhanin J. Involvement of isk-associated k+ channel in heart rate control


Vita

Daniel C. Bartos
Department of Physiology
University of Kentucky, Lexington, KY

EDUCATION

2009-2013 Graduate School
University of Kentucky College of Medicine
Department of Physiology
Lexington, KY
Expected defense: May 6, 2013

2004-2008 B.S., University of Kentucky
Lexington, KY

Wexford, PA

RESEARCH EXPERIENCE

2009-present Graduate Student
Department of Physiology
University of Kentucky
Lexington, KY

2009 Laboratory Technician Senior
Department of Physiology
University of Kentucky
Lexington, KY

2008-2009 Laboratory Technician
Department of Physiology
University of Kentucky
Lexington, KY

2007-2008 Student Technician
Department of Physiology
University of Kentucky
Lexington, KY

2005 Research Intern
Department of Immunogenetics
Children’s Hospital of Pittsburgh
University of Pittsburgh Medical Center
2004 Research Assistant  Department of Endocrinology
Children’s Hospital of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

GRANTS AND AWARDS
2012 University of Kentucky, Gill Heart 15th Annual Cardiovascular Research Day
2nd Place Graduate Student Poster

2012 University of Kentucky, Department of Physiology Biennial Retreat
1st Place Graduate Student Poster

2011-2013 American Heart Association Predoctoral Fellowship
Great Rivers Affiliate
11PRE737003

2010-2011 T-32 NIH "Interdisciplinary Cardiovascular Training Grant"
T32 HL072743

2010 University of Kentucky Center for Muscle Biology Fall Retreat
2nd Place Graduate Student Poster

2007 University of Kentucky Center for Muscle Biology
Summer Undergraduate Research Grant

PEER REVIEWED ARTICLES


Regulation of Scn5a and Cardiac Excitability." *AJP-Cell Physiology.* Epub 2013 Jan 30. PMID: 23364267


**PLATFORM PRESENTATIONS/SEMINARS**


2. **Bartos DC**. "The Contribution of Kv7.1 to the Cardiac Action Potential and Arrhythmogenesis." University of Kentucky, Department of Physiology Seminar Series. March 14, 2012


4. **Bartos DC**, Smith JL, Kilby JA, January CT, and Delisle BP. "Wild-Type KCNQ1 Modulates the Gating of the LQT1 Mutation R231C." Biophysical Society’s 53rd Annual Meeting (Boston, MA) 2009
PUBLISHED ABSTRACTS


5. **Bartos DC**, Giudicessi J, Tester DJ, Ackerman MJ, and Delisle BP. “Protracted QTc Prolongation following Treadmill Testing Identifies a Type 1 Long QT Mutation that is Resistant to PKA Activation.” Cardiac Electrophysiology Society Annual Meeting. (Los Angeles, CA) 2012


10. Burgess DE, **Bartos DC**, Schmidt ES, and Delisle BP. “A computational model for the effect that a KCNQ1 mutation linked to Jervell and Lange-
Nielson syndrome has on human cardiac action potential duration.”
Biophysical Society’s 55th Annual Meeting (Baltimore, MD) 2011
11. Smith JL, McBride CM, Bartos DC, January CT, and Delisle BP. “Microtubule Dependent Mechanisms Regulate the Trafficking Deficient Phenotype of hERG Mutations Linked to Long QT Syndrome.” Biophysical Society’s 54th Annual Meeting (San Francisco, CA) 2010
13. Bartos DC, Smith JL, Klby JA, January CT, and Delisle BP. “Wild-Type KCNQ1 Modulates the Gating of the LQT1 Mutation R231C.” Biophysical Society 53rd Annual Meeting (Boston, MA) 2009
14. Smith JL, Bartos DC, January CT, and Delisle BP. “Trafficking-deficient LQT2 Mutations Disrupt Different Steps of hERG Channel Transport.” Biophysical Society 53rd Annual Meeting (Boston, MA) 2009

POSTER PRESENTATIONS
1. Bartos DC, Guidicessi J, Burgess DE, Tester DJ, Ackerman MJ, and Delisle BP. “Long QT type 1 patients with abnormal QTc recovery latency have a KCNQ1 mutation that is insensitive to PKA.” Gordon Research Conference: Cardiac Arrhythmia Mechanisms (Ventura, CA) 2013
5. Bartos DC, Guidicessi J, Tester DJ, Ackerman MJ, and Delisle BP. “Protracted QTc Prolongation following Treadmill Testing Identifies a Type 1 Long QT Mutation that is Resistant to PKA Activation.” Cardiac Electrophysiology Society Annual Meeting. (Los Angeles, CA) 2012


12. Burgess DE, **Bartos DC**, Schmidt ES, and Delisle BP. “A computational model for the effect that a KCNQ1 mutation linked to Jervell and Lange-Nielson syndrome has on human cardiac action potential duration.” Biophysical Society 55th Annual Meeting (Baltimore, MD) 2011


16. **Bartos DC** and Delisle BP. “A KCNQ1 Mutation Linked to Familial Atrial Fibrillation and Type 1 Long QT Syndrome.” Gill Heart Institute 12th Annual Cardiovascular Research Day (Lexington, KY) 2009

17. **Bartos DC**, Smith JL, January CT, and Delisle BP. “WT-Kv7.1 Causes the Loss of Function Phenotype for the Type 1 Long QT-linked R231C Mutation.” International Society of Heart Research—North American Section Meeting (Baltimore, MD) 2009
18. Smith JL, Bartos DC, January CT, and Delisle BP. “The plasmalemmal expression of Human-ether-a-go-go Related K⁺ channels is not dependant on microtubule assembly.” International Society of Heart Research—North American Section Meeting (Baltimore, MD) 2009

19. Smith JL, Bartos DC, January CT, and Delisle BP. “Trafficking-deficient LQT2 Mutations Disrupt Different Steps of hERG Channel Transport.” Biophysical Society 53rd Annual Meeting (Boston, MA) 2009


SOCIETY MEMBERSHIPS

2009-present American Heart Association
2009-present Biophysical Society
2012-present Cardiac Electrophysiology Society
2011-present Heart Rhythm Society
2010-present Science/AAAS
2007-present University of Kentucky Center for Muscle Biology

TEACHING EXPERIENCE

2011-present University of Kentucky—PGY207
Teaching Assistant for Undergraduate General Physiology Recitation (PGY206)

2009-present University of Kentucky—Private tutor
Tutor for undergraduate classes including: Biology, Chemistry, Physiology, Cell Biology, or Biochemistry